Details of Disease

General Information of Disease (ID: DISMNGZ0)

• Disease Name: Thyroid gland carcinoma
• Synonyms: thyroid cancer; head and neck cancer, thyroid; thyroid gland cancer; cancer of thyroid; cancer of the thyroid; carcinoma of thyroid gland; thyroid carcinoma; thyroid gland carcinoma; carcinoma of thyroid; carcinoma of the thyroid; carcinoma of the thyroid gland
• Definition: A carcinoma arising from the thyroid gland. It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic.
• Disease Hierarchy:
  DIS3VLDH: Thyroid cancer
  DISH9F1N: Carcinoma
  DISMNGZ0: Thyroid gland carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0015075
  MESH ID: D013964
  UMLS CUI: C0549473
  MedGen ID: 107811
  HPO ID: HP:0002890
  Orphanet ID: 100088

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 155 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BMP1	TT0L58T	Limited	Biomarker	[1]
CALCA	TTVSFJW	Limited	Genetic Variation	[2]
DICER1	TTTEOPU	Limited	Genetic Variation	[3]
DUSP5	TTZN92A	Limited	Biomarker	[4]
ENPP2	TTSCIM2	Limited	Biomarker	[5]
FAP	TTGPQ0F	Limited	Altered Expression	[6]
FYN	TT2B9KF	Limited	Altered Expression	[7]
GJB3	TTVRQ8L	Limited	Altered Expression	[8]
IL32	TTD4G7L	Limited	Biomarker	[9]
KSR1	TTHL1TV	Limited	Posttranslational Modification	[10]
LASP1	TTZJA87	Limited	Biomarker	[11]
MAP4K4	TT6NI13	Limited	Altered Expression	[12]
MMP11	TTZW4MV	Limited	Biomarker	[13]
MUC15	TTGQ6MI	Limited	Biomarker	[14]
NOX4	TTQRBSJ	Limited	Biomarker	[15]
PRKAR1A	TTNAHEX	Limited	Genetic Variation	[16]
RAPGEF3	TTOE7I0	Limited	Biomarker	[17]
RAPGEF4	TTOS63B	Limited	Biomarker	[17]
S1PR2	TTVSMOH	Limited	Biomarker	[18]
SCN10A	TT90XZ8	Limited	Biomarker	[19]
SDHD	TTVH9W8	Limited	Genetic Variation	[20]
SLC26A4	TT7X02I	Limited	Genetic Variation	[21]
SLC6A9	TTHJTF7	Limited	Biomarker	[22]
SPHK1	TTOHFIY	Limited	Biomarker	[23]
STOML2	TTOI329	Limited	Altered Expression	[24]
TIAM1	TTNU6I5	Limited	Biomarker	[25]
TNFRSF13B	TTL9OD4	Limited	Altered Expression	[26]
TSG101	TTHU7JA	Limited	Biomarker	[27]
YES1	TT0SQ8J	Limited	Altered Expression	[28]
ATIC	TT9NVXQ	Disputed	Biomarker	[29]
FGF19	TTGCH11	Disputed	Biomarker	[30]
SORT1	TTRX9AV	Disputed	Biomarker	[31]
STK4	TTCPLVN	Disputed	Biomarker	[32]
ARAF	TT5TURO	moderate	Genetic Variation	[33]
BCAT2	TTF9OQ6	moderate	Altered Expression	[34]
CCNE2	TTLDRGX	moderate	Altered Expression	[35]
CNTN1	TTPR8FK	moderate	Biomarker	[36]
CSF2	TTNYZG2	moderate	Biomarker	[5]
EPO	TTQG4NR	moderate	Biomarker	[37]
EPOR	TTAUX24	moderate	Biomarker	[37]
IDH1	TTV2A1R	moderate	Genetic Variation	[38]
IFNA2	TTSIUJ9	moderate	Therapeutic	[39]
LIMK1	TTWL9TY	moderate	Biomarker	[40]
MAPKAP1	TTWDKCL	moderate	Altered Expression	[41]
MVD	TTE5J6X	moderate	Altered Expression	[42]
NDUFA13	TTRU1NG	moderate	Biomarker	[43]
PDGFA	TTSM78N	moderate	Biomarker	[5]
PPARG	TTT2SVW	moderate	Genetic Variation	[44]
PRKCQ	TT1MS7X	moderate	Biomarker	[45]
PTGES2	TTWU04I	moderate	Biomarker	[46]
RUNX2	TTD6SZ8	moderate	Altered Expression	[47]
RXRA	TT6PEUO	moderate	Biomarker	[48]
SSTR2	TTZ6T9E	moderate	Altered Expression	[49]
TPCN1	TTODQE2	moderate	Biomarker	[50]
TRPC1	TTA76X0	moderate	Biomarker	[51]
VDAC1	TTAMKGB	moderate	Altered Expression	[52]
WNK1	TTJ9UMX	moderate	Posttranslational Modification	[53]
XRCC5	TTCB9KW	moderate	Altered Expression	[54]
ACVR1B	TTPKHTZ	Strong	Altered Expression	[55]
AGK	TTJETQC	Strong	Genetic Variation	[56]
AKT3	TTO6SGY	Strong	Biomarker	[57]
ALK	TTPMQSO	Strong	Biomarker	[58]
ARG2	TTV1AG6	Strong	Biomarker	[59]
ATM	TTKBM7V	Strong	Genetic Variation	[60]
BRD4	TTSRAOU	Strong	Biomarker	[61]
BUB1	TT78309	Strong	Altered Expression	[62]
CA12	TTSYM0R	Strong	Biomarker	[63]
CBX7	TTBN3HC	Strong	Biomarker	[64]
CCKBR	TTVFO0U	Strong	Altered Expression	[65]
CCL2	TTNAY0P	Strong	Biomarker	[66]
CCND1	TTFCJ7S	Strong	Biomarker	[67]
CDH1	TTLAWO6	Strong	Genetic Variation	[68]
CDH5	TTXLCFO	Strong	Posttranslational Modification	[69]
CDH6	TT9QHUK	Strong	Biomarker	[70]
CDK2	TT7HF4W	Strong	Biomarker	[71]
CDK5	TTL4Q97	Strong	Biomarker	[72]
CDKN1B	TTLGFVW	Strong	Biomarker	[73]
CHEK2	TT9ABMF	Strong	Biomarker	[74]
CXCL10	TTQOVYA	Strong	Biomarker	[75]
CXCR1	TTMWT8Z	Strong	Altered Expression	[76]
CXXC5	TTVS4C3	Strong	Altered Expression	[77]
CYP19A1	TTSZLWK	Strong	Altered Expression	[78]
CYP24A1	TT82UI1	Strong	Biomarker	[79]
DPEP1	TTYUENF	Strong	Genetic Variation	[80]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[81]
F9	TTFEZ5Q	Strong	Genetic Variation	[82]
FGFR4	TT1KX2S	Strong	Biomarker	[30]
GAS6	TT69QD2	Strong	Biomarker	[53]
GPER1	TTDSB34	Strong	Biomarker	[83]
GRK2	TTAZ3MN	Strong	Altered Expression	[84]
HIF1A	TTSN6QU	Strong	Genetic Variation	[85]
HIPK2	TTOB49C	Strong	Biomarker	[86]
HLA-G	TTLKFB3	Strong	Biomarker	[87]
HMGA1	TTBA219	Strong	Biomarker	[88]
HMGA2	TTSTVM0	Strong	Biomarker	[89]
HRAS	TT28ZON	Strong	Biomarker	[90]
IDUA	TT0IUKX	Strong	Biomarker	[91]
IL1R2	TT51DEV	Strong	Genetic Variation	[92]
IMP3	TTEJA2R	Strong	Biomarker	[93]
ITCH	TT5SEWD	Strong	Biomarker	[94]
KEAP1	TT3Z6Y9	Strong	Biomarker	[95]
KLB	TTARBVH	Strong	Altered Expression	[96]
KRAS	TTM8FR7	Strong	Biomarker	[97]
KRT19	TT3JF9E	Strong	Altered Expression	[98]
LGR4	TTY6C71	Strong	Altered Expression	[99]
MAP2K1	TTIDAPM	Strong	Biomarker	[100]
MAP2K7	TT6QY3J	Strong	Genetic Variation	[101]
MCM7	TT1RM3F	Strong	Altered Expression	[102]
MRGPRX1	TTIX6PK	Strong	Genetic Variation	[103]
MTOR	TTCJG29	Strong	Biomarker	[104]
NCOA4	TT8OY02	Strong	Altered Expression	[36]
NR1D1	TTAD1O8	Strong	Genetic Variation	[105]
NRAS	TTW2R9X	Strong	Biomarker	[106]
NRG1	TTEH395	Strong	Biomarker	[107]
NTRK3	TTXABCW	Strong	Biomarker	[16]
OGFR	TT6IEYX	Strong	Biomarker	[108]
PAM	TTF4ZPC	Strong	Biomarker	[109]
PDPK1	TTYMGWX	Strong	Biomarker	[110]
PLA2R1	TTHKW7D	Strong	Altered Expression	[111]
PPARGC1B	TTKSQ3W	Strong	Genetic Variation	[85]
PPM1D	TTENJAB	Strong	Genetic Variation	[74]
PTGS2	TTVKILB	Strong	Biomarker	[112]
PTPRJ	TTWMKXP	Strong	Genetic Variation	[113]
RARB	TTISP28	Strong	Biomarker	[114]
RGS4	TTGTKX9	Strong	Biomarker	[115]
RHBDF2	TTH1ZOP	Strong	Biomarker	[116]
RXFP1	TTMAHD1	Strong	Altered Expression	[117]
RXRB	TTKLV96	Strong	Biomarker	[118]
SERPINB5	TT1KW50	Strong	Posttranslational Modification	[119]
SLC1A3	TT8WRDA	Strong	Altered Expression	[120]
SLCO2B1	TTDL3UZ	Strong	Biomarker	[121]
SMAD3	TTHQZV7	Strong	Biomarker	[122]
SORD	TTLSRBZ	Strong	Genetic Variation	[123]
SSTR3	TTJX3UE	Strong	Altered Expression	[124]
STC1	TTDLUER	Strong	Biomarker	[125]
TACSTD2	TTP2HE5	Strong	Biomarker	[126]
TEP1	TTQGAVX	Strong	Biomarker	[127]
TERT	TTQY2EJ	Strong	Genetic Variation	[128]
THBS1	TTKI0H1	Strong	Biomarker	[129]
THRA	TTTSEPU	Strong	Genetic Variation	[105]
THRB	TTGER3L	Strong	Biomarker	[130]
TKTL1	TTNQ1J3	Strong	Biomarker	[131]
TP53BP1	TTX4UE9	Strong	Altered Expression	[132]
TTK	TTP7EGM	Strong	Biomarker	[91]
TXNIP	TTTLDZK	Strong	Biomarker	[133]
VCP	TTHNLSB	Strong	Altered Expression	[134]
WRN	TT2H5WQ	Strong	Genetic Variation	[135]
CCR6	TTFDB30	Definitive	Biomarker	[136]
ELAVL1	TTPC9D0	Definitive	Biomarker	[137]
FOLH1	TT9G4N0	Definitive	Altered Expression	[138]
GAP43	TTSGLN5	Definitive	Biomarker	[139]
IL13RA2	TTMPZ7V	Definitive	Biomarker	[140]
PAK1	TTFN95D	Definitive	Biomarker	[141]
PKM	TT4LOT8	Definitive	Biomarker	[142]
SLIT2	TTDWK85	Definitive	Biomarker	[143]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC16A2	DTQ8MP1	Limited	Altered Expression	[144]
SLC5A8	DTE3TAW	moderate	Genetic Variation	[21]

This Disease Is Related to 13 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYB5R3	DE4A3BL	Limited	Biomarker	[145]
HIF1AN	DEY1CBW	Limited	Biomarker	[146]
MT1A	DE5ME8A	Limited	Biomarker	[147]
PTGDS	DER3H9C	Limited	Altered Expression	[148]
HPGD	DEHKSC6	moderate	Therapeutic	[149]
UPP1	DEFZWAX	moderate	Altered Expression	[150]
BAAT	DERA3OF	Strong	Genetic Variation	[105]
CYP1A1	DE6OQ3W	Strong	Altered Expression	[151]
GGCT	DEKW6PB	Strong	Biomarker	[152]
GSTM1	DEYZEJA	Strong	Biomarker	[153]
GSTT1	DE3PKUG	Strong	Genetic Variation	[153]
NNMT	DECVGJ3	Strong	Altered Expression	[154]
AKR1C2	DEOY5ZM	Definitive	Altered Expression	[155]

This Disease Is Related to 318 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AFM	OTPOR8IO	Limited	Biomarker	[156]
AGPS	OTFBFPV4	Limited	Biomarker	[157]
AKAP4	OTL4Z99V	Limited	Biomarker	[158]
AMBP	OTLU8GU8	Limited	Altered Expression	[159]
ANO5	OTOW8R6H	Limited	Altered Expression	[160]
ATG9B	OTJMJZW8	Limited	Biomarker	[161]
BAG3	OTVXYUDQ	Limited	Altered Expression	[162]
BASP1	OTF4VS5G	Limited	Altered Expression	[163]
BHLHE41	OTY9GJ1Y	Limited	Biomarker	[164]
BID	OTOSHSHU	Limited	Biomarker	[161]
BLM	OTEJOAJX	Limited	Altered Expression	[165]
BTG2	OTZF6K1H	Limited	Altered Expression	[166]
BUB3	OTU91HAU	Limited	Genetic Variation	[62]
C14orf93	OTMHTPMZ	Limited	Biomarker	[167]
CCL15	OTOGZ85M	Limited	Biomarker	[168]
CETN1	OTGQ8JOZ	Limited	Altered Expression	[145]
CITED1	OTUJQ3VL	Limited	Biomarker	[169]
COPZ1	OTJXGQQW	Limited	Biomarker	[170]
DIAPH1	OTZBYPLH	Limited	Biomarker	[145]
DIPK2A	OTL1DBIM	Limited	Biomarker	[145]
EHF	OTY6TPWD	Limited	Altered Expression	[171]
EIF4A3	OTYYFE7K	Limited	Biomarker	[172]
EPB41L4A	OTJAFRTL	Limited	Genetic Variation	[173]
FHOD3	OT1WUBQX	Limited	Genetic Variation	[174]
FXYD5	OT81DIOD	Limited	Altered Expression	[159]
FZD8	OTZ9IRFL	Limited	Altered Expression	[175]
GATAD2A	OTFM8D3O	Limited	Biomarker	[176]
HMGN4	OTD7GPRL	Limited	Biomarker	[177]
HORMAD2	OTL2ENWI	Limited	Altered Expression	[178]
HUWE1	OTFH6BJS	Limited	Biomarker	[179]
IFT88	OTDR3VBD	Limited	Altered Expression	[180]
IGF2BP3	OTB97VIK	Limited	Altered Expression	[181]
IL17RB	OT0KDNSF	Limited	Altered Expression	[182]
ING5	OTRNNSFM	Limited	Biomarker	[183]
KIR2DS5	OTXLEN11	Limited	Genetic Variation	[184]
LETM1	OT8N4MRU	Limited	Altered Expression	[185]
LRP4	OTO4M459	Limited	Altered Expression	[186]
LRRC34	OTSPZLKF	Limited	Genetic Variation	[173]
MREG	OT0LUIRG	Limited	Biomarker	[187]
NCOA5	OTOGWTWB	Limited	Biomarker	[188]
NFIL3	OTQH9HM3	Limited	Biomarker	[189]
NRCAM	OT80HHQ2	Limited	Biomarker	[190]
PAX8	OTRPD9MI	Limited	Biomarker	[191]
PCBP1	OTHN0TD7	Limited	Altered Expression	[192]
PCNX2	OT90S9W6	Limited	Genetic Variation	[173]
PEG3	OTHQW98S	Limited	Biomarker	[193]
PIWIL2	OT1PXQIF	Limited	Biomarker	[194]
POT1	OTNBXJCQ	Limited	Genetic Variation	[195]
POU5F1B	OT0FKQ51	Limited	Genetic Variation	[196]
RAB11A	OTC4FW0J	Limited	Altered Expression	[197]
RBMY1A1	OTM2F25H	Limited	Genetic Variation	[198]
RBP2	OTR8QG5V	Limited	Biomarker	[199]
RCC1	OT25AGMB	Limited	Genetic Variation	[200]
RNASE1	OTKZ7CO9	Limited	Altered Expression	[201]
SDF4	OTQ7WFYW	Limited	Altered Expression	[145]
SGSM3	OTIB1P8A	Limited	Altered Expression	[91]
SLC35F2	OTSAD4EQ	Limited	Biomarker	[202]
SPRY4	OT2VK9N0	Limited	Biomarker	[203]
SRGAP1	OTL89HGW	Limited	Genetic Variation	[204]
SRP72	OTPV73W7	Limited	Altered Expression	[174]
STK17B	OT4NYNO8	Limited	Altered Expression	[205]
SYTL2	OTUIOWKL	Limited	Altered Expression	[24]
TCP1	OT1MGUX9	Limited	Biomarker	[206]
TCTN1	OTG5KEV8	Limited	Biomarker	[207]
TINAGL1	OTZZO56M	Limited	Altered Expression	[208]
TPM3	OT5RU5G6	Limited	Biomarker	[16]
TRIM29	OT2DNESG	Limited	Altered Expression	[209]
TRIM44	OT0B1T2B	Limited	Biomarker	[210]
ADGRE2	OTUYJVYG	Disputed	Altered Expression	[211]
ADGRE5	OTTSB84Q	Disputed	Altered Expression	[211]
DCTN6	OTI8PIN9	Disputed	Biomarker	[212]
DDT	OTF5HTYL	Disputed	Biomarker	[213]
FOXE1	OT5IR5IT	Disputed	Altered Expression	[214]
GPD2	OTV232Y7	Disputed	Biomarker	[215]
IFI27	OTI2XGIT	Disputed	Biomarker	[212]
IQGAP1	OTZRWTGA	Disputed	Altered Expression	[216]
MYO1F	OTOAV4AR	Disputed	Biomarker	[217]
NCOA1	OTLIUJQD	Disputed	Altered Expression	[218]
NEMP1	OTWN3S47	Disputed	Biomarker	[219]
PELI1	OTMLBCLC	Disputed	Biomarker	[220]
PRDM6	OTKY12D9	Disputed	Biomarker	[220]
PRIMA1	OT9ITT3P	Disputed	Posttranslational Modification	[221]
PSMD9	OT6Y5CC3	Disputed	Biomarker	[212]
RASAL1	OTAHUNN7	Disputed	Biomarker	[222]
SDHB	OTRE1M1T	Disputed	Genetic Variation	[223]
TCIM	OTARUXQF	Disputed	Genetic Variation	[224]
TICAM2	OTK7GIJ5	Disputed	Biomarker	[212]
TMED7	OTONO8E6	Disputed	Biomarker	[212]
TMPRSS4	OTCCGY2K	Disputed	Altered Expression	[225]
ABCE1	OTH19LOA	moderate	Biomarker	[226]
ABI3	OTQTDSHP	moderate	Posttranslational Modification	[227]
ARHGEF7	OT9BPJCL	moderate	Altered Expression	[228]
ASCC1	OTH4VAP9	moderate	Altered Expression	[228]
ATP5F1E	OTMPLAIS	moderate	Altered Expression	[229]
BCAM	OTHZOPSD	moderate	Biomarker	[34]
CARD11	OTRCTLYC	moderate	Altered Expression	[230]
CCNG2	OTII38K2	moderate	Biomarker	[71]
CDH16	OTR0GE9G	moderate	Biomarker	[231]
CPSF2	OTU6QXZE	moderate	Biomarker	[232]
CRYGD	OTW29JC4	moderate	Genetic Variation	[233]
CTDSPL	OTZJ0CZK	moderate	Biomarker	[234]
DUSP4	OT6WAO12	moderate	Biomarker	[235]
GNB3	OTA6HYBA	moderate	Genetic Variation	[236]
GORASP1	OTQS91S7	moderate	Posttranslational Modification	[53]
GRB14	OTFET2YM	moderate	Altered Expression	[237]
HLTF	OTRX2OSF	moderate	Altered Expression	[238]
HOXC10	OT5WF17M	moderate	Biomarker	[239]
MSH6	OT46FP09	moderate	Biomarker	[240]
MT1G	OTAV1OCR	moderate	Altered Expression	[241]
NIBAN1	OTYOLI12	moderate	Biomarker	[242]
PA2G4	OT7IG7HT	moderate	Biomarker	[222]
PDZK1IP1	OTWA6M5K	moderate	Altered Expression	[243]
PPP6C	OTR1STMJ	moderate	Biomarker	[45]
RBX1	OTYA1UIO	moderate	Biomarker	[244]
REC8	OT6JAVXE	moderate	Altered Expression	[245]
RTN4IP1	OTHUZANE	moderate	Altered Expression	[246]
SASH1	OTQA8BD4	moderate	Biomarker	[247]
SERPINA5	OTTZXPGD	moderate	Biomarker	[235]
SLIT3	OTU8MKEU	moderate	Biomarker	[248]
SOX17	OT9H4WWE	moderate	Posttranslational Modification	[249]
SPC24	OT1HVYV4	moderate	Altered Expression	[250]
SYT1	OTVTPOI6	moderate	Posttranslational Modification	[53]
TBX15	OTAZ9QDX	moderate	Biomarker	[251]
TCF7L1	OTTUTF0O	moderate	Biomarker	[48]
TPR	OTUBBA4W	moderate	Biomarker	[48]
ABI3BP	OTW8DN50	Strong	Biomarker	[252]
ACP1	OTJ9CKLU	Strong	Biomarker	[253]
AFAP1L2	OTJBI0VN	Strong	Altered Expression	[254]
AKAP9	OT7Z2YRP	Strong	Biomarker	[255]
ANKRD36B	OT3MW415	Strong	Biomarker	[256]
ATF1	OT251CI0	Strong	Altered Expression	[257]
ATF2	OTNIZPEA	Strong	Altered Expression	[258]
BUB1B	OT8KME51	Strong	Biomarker	[62]
C1D	OTI9PMN1	Strong	Biomarker	[259]
CBX1	OT2L4XZX	Strong	Biomarker	[260]
CBX5	OT8VYY84	Strong	Biomarker	[260]
CCDC6	OTXRQDYG	Strong	Genetic Variation	[82]
CCDC80	OTOZSYEM	Strong	Biomarker	[261]
CD63	OT2UGZA9	Strong	Altered Expression	[262]
CDC23	OTC4O83E	Strong	Biomarker	[263]
CDH17	OT9EV2XK	Strong	Altered Expression	[264]
CDSN	OTQW4HV6	Strong	Biomarker	[265]
CENPJ	OTZCQZN5	Strong	Biomarker	[266]
CITED2	OT812TV7	Strong	Biomarker	[267]
CLEC4D	OTT7X1UC	Strong	Genetic Variation	[60]
CORO1A	OTVAZOHC	Strong	Altered Expression	[268]
CREB3L2	OT09MHV0	Strong	Genetic Variation	[269]
CREB5	OTJDUJPI	Strong	Biomarker	[270]
CRIP1	OT0EICG3	Strong	Altered Expression	[271]
CRIP2	OTVVJSYX	Strong	Biomarker	[271]
DACT2	OTNLCC0K	Strong	Posttranslational Modification	[272]
DMBT1	OTVNU9D9	Strong	Altered Expression	[110]
DR1	OTR081M4	Strong	Biomarker	[273]
DUOX2	OTU14HCN	Strong	Altered Expression	[274]
DUSP6	OT4H6RKW	Strong	Biomarker	[4]
ECM1	OT1K65VW	Strong	Altered Expression	[225]
EFNB2	OT0DCUOM	Strong	Altered Expression	[275]
ENDOU	OTB7OF7Y	Strong	Biomarker	[276]
ERRFI1	OT7VZ2IZ	Strong	Biomarker	[277]
EXOSC6	OTAC10N6	Strong	Biomarker	[276]
FAM107B	OT5RG4J0	Strong	Altered Expression	[278]
FCGBP	OT63T6XQ	Strong	Altered Expression	[279]
FGD3	OTIH6283	Strong	Biomarker	[280]
FGF3	OT9PK2SI	Strong	Biomarker	[281]
FLCN	OTVM78XM	Strong	Genetic Variation	[282]
FOXA1	OTEBY0TD	Strong	Altered Expression	[283]
FSD1	OT8P6PT3	Strong	Biomarker	[284]
FSD1L	OTBQ48RF	Strong	Biomarker	[284]
GADD45G	OT8V1J4M	Strong	Biomarker	[285]
GINS2	OT974IYI	Strong	Biomarker	[267]
GOLGA5	OTG6HB6U	Strong	Genetic Variation	[286]
GOT2	OT6XBWN0	Strong	Biomarker	[287]
GPLD1	OTUUQOVY	Strong	Altered Expression	[288]
GPR68	OT1NXSMN	Strong	Altered Expression	[289]
GYPA	OTABU4YV	Strong	Genetic Variation	[290]
HABP2	OTAUIPW0	Strong	Genetic Variation	[291]
HEMGN	OTZPYUOY	Strong	Biomarker	[292]
HLA-DQA2	OT1DH0N9	Strong	Altered Expression	[293]
HNRNPD	OT5UO1FA	Strong	Altered Expression	[294]
HNRNPF	OTSMBXMF	Strong	Biomarker	[295]
HOOK1	OTTTKV7V	Strong	Biomarker	[296]
HOPX	OTBSR6C9	Strong	Altered Expression	[297]
HSF2	OTXNJIJ9	Strong	Biomarker	[111]
ID3	OTUULW5Z	Strong	Altered Expression	[298]
IGFBP4	OT2HZRBD	Strong	Biomarker	[299]
INF2	OT8ZM13C	Strong	Biomarker	[300]
INSL3	OT7KUNTE	Strong	Altered Expression	[301]
INTS2	OT2N5TCK	Strong	Biomarker	[281]
ITGA3	OTBCH21D	Strong	Biomarker	[302]
IYD	OT8BQWTE	Strong	Altered Expression	[303]
KLF17	OT5NWVP7	Strong	Biomarker	[304]
KLLN	OTV3FPH0	Strong	Genetic Variation	[305]
LRG1	OTLD0KWA	Strong	Biomarker	[306]
LTBP2	OTS88GSD	Strong	Biomarker	[307]
MADD	OTUFYVGG	Strong	Biomarker	[308]
MAPK4	OTVWWUYS	Strong	Altered Expression	[309]
MASTL	OTQ7YKK5	Strong	Biomarker	[310]
MIB2	OTJCC3HS	Strong	Biomarker	[304]
MLF1	OTC5BKHU	Strong	Biomarker	[311]
MMP20	OT16S5S3	Strong	Altered Expression	[312]
MMRN1	OT7ZNYHT	Strong	Genetic Variation	[225]
MPEG1	OT7DAO0F	Strong	Biomarker	[91]
MR1	OTZU3XX7	Strong	Altered Expression	[313]
MRGPRX3	OTRKCCDS	Strong	Genetic Variation	[103]
MRGPRX4	OTOBHZVA	Strong	Genetic Variation	[103]
MRO	OT5U38CP	Strong	Biomarker	[314]
MT1M	OTVT8PLU	Strong	Altered Expression	[315]
NAPSA	OT6F8IAL	Strong	Biomarker	[316]
ND1	OTCLGIXV	Strong	Genetic Variation	[317]
NDRG2	OT5L6KD7	Strong	Altered Expression	[318]
NECTIN1	OTTE5ZR6	Strong	Altered Expression	[319]
NPC2	OTE9UEJC	Strong	Biomarker	[320]
NR2F1	OTGWZWYL	Strong	Altered Expression	[321]
NRARP	OTMYHUV2	Strong	Biomarker	[322]
OXA1L	OTS0BFRD	Strong	Biomarker	[323]
PARP4	OTXBK59G	Strong	Biomarker	[324]
PEA15	OTKCKTSX	Strong	Altered Expression	[325]
PHF20	OTCBVH5P	Strong	Biomarker	[304]
PJA2	OT45TMC4	Strong	Altered Expression	[326]
PPL	OTTM4WDO	Strong	Biomarker	[270]
PPP1R15A	OTYG179K	Strong	Altered Expression	[327]
PRDM2	OT8L7CGX	Strong	Biomarker	[328]
PROK1	OT8S7RUG	Strong	Biomarker	[329]
PROX1	OT68R6IO	Strong	Altered Expression	[330]
PSME3	OTSTC4YY	Strong	Biomarker	[331]
PTCH2	OTOQ0K9V	Strong	Biomarker	[332]
PTMA	OT2W4T1M	Strong	Biomarker	[333]
PTMS	OT9PS4Q0	Strong	Biomarker	[333]
PTPRF	OTH5KF2D	Strong	Biomarker	[50]
PTTG1	OTIMYS4W	Strong	Biomarker	[334]
PTTG1IP	OTX21QTE	Strong	Biomarker	[334]
RAC2	OTAOHFNH	Strong	Altered Expression	[335]
RAD52	OT0OTDHI	Strong	Genetic Variation	[336]
RAMP1	OT7UT2XB	Strong	Biomarker	[337]
RASIP1	OTCRY2AN	Strong	Altered Expression	[47]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[338]
RASSF10	OTGB7EBG	Strong	Posttranslational Modification	[339]
RASSF2	OT2JHDO4	Strong	Biomarker	[340]
RBBP4	OTG3BT3M	Strong	Biomarker	[341]
RCAN1	OT1MVXC7	Strong	Altered Expression	[342]
REV1	OTHIKICX	Strong	Altered Expression	[343]
RGCC	OTYJMLWM	Strong	Biomarker	[263]
RLN2	OTY3OG71	Strong	Altered Expression	[344]
RNF139	OT0PR1X5	Strong	Biomarker	[345]
RPL29	OTUFIBJL	Strong	Altered Expression	[346]
RPL36A	OT1LYV85	Strong	Biomarker	[277]
RPS27	OTFXKY7P	Strong	Biomarker	[91]
RREB1	OT62460U	Strong	Biomarker	[304]
RSPO2	OT3HHXU0	Strong	Altered Expression	[99]
RYR2	OT0PF19E	Strong	Altered Expression	[347]
SAGE1	OT4H6FFA	Strong	Biomarker	[348]
SCG5	OTXSJMT1	Strong	Biomarker	[63]
SDC4	OTKUVUGZ	Strong	Biomarker	[311]
SDS	OT5WTJ2M	Strong	Genetic Variation	[123]
SEC23B	OT2NFSIQ	Strong	Genetic Variation	[349]
SEC62	OTCWEL5F	Strong	Altered Expression	[350]
SIRT4	OT5S0J23	Strong	Altered Expression	[351]
SIRT7	OT5M4OT4	Strong	Altered Expression	[352]
SLURP1	OT89YD2E	Strong	Genetic Variation	[353]
SMG1	OTTS3SXE	Strong	Biomarker	[354]
SMURF1	OT5UIZR8	Strong	Biomarker	[355]
SNAI2	OT7Y8EJ2	Strong	Altered Expression	[356]
SNX5	OT6ZOWMU	Strong	Biomarker	[357]
SOD3	OTIOZQAB	Strong	Altered Expression	[358]
SOX15	OTTB37I1	Strong	Biomarker	[359]
SPAG9	OT45AHMB	Strong	Altered Expression	[360]
SSH2	OT8NCK82	Strong	Altered Expression	[361]
SSX2	OT2Z6RLL	Strong	Altered Expression	[362]
ST13	OTNML6UP	Strong	Altered Expression	[346]
STK3	OTLNSCQD	Strong	Biomarker	[340]
STRN	OTLOZL5I	Strong	Altered Expression	[363]
TAF1	OTDYS5G4	Strong	Biomarker	[287]
TAS2R38	OTX5MM36	Strong	Genetic Variation	[82]
TCEAL4	OTX24CQI	Strong	Altered Expression	[364]
TFF3	OTJJDRTU	Strong	Altered Expression	[365]
TFG	OT2KJENI	Strong	Biomarker	[366]
TIMM44	OTXP7MXN	Strong	Genetic Variation	[367]
TIMP4	OT8A68SW	Strong	Altered Expression	[356]
TMEM184C	OTCA2HUW	Strong	Altered Expression	[368]
TMSB10	OTLVZ13T	Strong	Biomarker	[369]
TOMM20	OT76TPR2	Strong	Biomarker	[370]
TRAP1	OTNG0L8J	Strong	Biomarker	[371]
TSC2	OT47LWI9	Strong	Biomarker	[372]
TSPAN13	OTCS9BZY	Strong	Altered Expression	[373]
TTF1	OT4K90WD	Strong	Altered Expression	[316]
TTF2	OT5LJOWM	Strong	Biomarker	[374]
ALX4	OTNS9A29	Definitive	Altered Expression	[375]
AMPD1	OTU17BCI	Definitive	Altered Expression	[376]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[377]
BMP8A	OT1997IN	Definitive	Altered Expression	[378]
CAVIN2	OTFHHDRU	Definitive	Biomarker	[379]
DEUP1	OTXLM86J	Definitive	Altered Expression	[380]
EIF1AX	OTWG2LAB	Definitive	Biomarker	[381]
ETFA	OTXX61VZ	Definitive	Biomarker	[382]
FBLIM1	OTFHXMON	Definitive	Altered Expression	[383]
FUCA1	OTW71IK4	Definitive	Altered Expression	[384]
GOPC	OTRBGH71	Definitive	Altered Expression	[383]
HCP5	OTV0YRI8	Definitive	Biomarker	[385]
IGSF1	OT3XD6U2	Definitive	Altered Expression	[386]
INPP4B	OTLROA7G	Definitive	Altered Expression	[387]
KIF22	OTY6X6BL	Definitive	Biomarker	[388]
KLHL14	OTYOS55H	Definitive	Biomarker	[389]
LIMD2	OTSIFTD8	Definitive	Biomarker	[390]
LRIG1	OTY5HZN5	Definitive	Genetic Variation	[391]
MIEF1	OTFSP3FS	Definitive	Biomarker	[392]
NOC2L	OTNT7R33	Definitive	Biomarker	[393]
NOVA1	OT6A9KHY	Definitive	Biomarker	[394]
OBP2A	OTBIJ5TI	Definitive	Biomarker	[388]
PATZ1	OT0X9WGR	Definitive	Biomarker	[395]
PKHD1L1	OTREFCAA	Definitive	Altered Expression	[396]
RAP1B	OTHEIIMM	Definitive	Altered Expression	[397]
RRS1	OTTNCZN6	Definitive	Biomarker	[398]
SHOC2	OTUNQ2CT	Definitive	Biomarker	[399]
SOSTDC1	OTAKDNSM	Definitive	Altered Expression	[189]
SPANXA1	OTMK3QIS	Definitive	Biomarker	[400]
TFAP2B	OTR1T8E9	Definitive	Altered Expression	[401]
TFCP2L1	OT7QIJ0X	Definitive	Biomarker	[402]
TRIP13	OTFM3TI9	Definitive	Altered Expression	[403]

References

• [1] Pathologic significance of a novel oncoprotein in thyroid cancer progression.Head Neck. 2017 Dec;39(12):2459-2469. doi: 10.1002/hed.24913. Epub 2017 Oct 11.
• [2] Falsely elevated thyroglobulin and calcitonin due to rheumatoid factor in non-relapsing thyroid carcinoma: A case report.Medicine (Baltimore). 2019 Feb;98(5):e14178. doi: 10.1097/MD.0000000000014178.
• [3] Neoplasm Risk Among Individuals With a Pathogenic Germline Variant in DICER1.J Clin Oncol. 2019 Mar 10;37(8):668-676. doi: 10.1200/JCO.2018.78.4678. Epub 2019 Feb 4.
• [4] DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.PLoS One. 2017 Sep 14;12(9):e0184861. doi: 10.1371/journal.pone.0184861. eCollection 2017.
• [5] Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer.Endocr Relat Cancer. 2015 Aug;22(4):593-607. doi: 10.1530/ERC-15-0045. Epub 2015 Jun 2.
• [6] Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma.Int J Oncol. 2007 Jul;31(1):59-67.
• [7] Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration.Cancer Biother Radiopharm. 2017 Nov;32(9):320-326. doi: 10.1089/cbr.2017.2218.
• [8] Ginsenoside improves papillary thyroid cancer cell malignancies partially through upregulating connexin 31.Kaohsiung J Med Sci. 2018 Jun;34(6):313-320. doi: 10.1016/j.kjms.2017.12.006. Epub 2018 Jan 17.
• [9] Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.Cell Oncol (Dordr). 2019 Oct;42(5):691-703. doi: 10.1007/s13402-019-00457-9. Epub 2019 Jun 14.
• [10] KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer.J Mol Endocrinol. 2015 Apr;54(2):115-24. doi: 10.1530/JME-14-0270. Epub 2015 Jan 21.
• [11] Silencing of LIM and SH3 Protein 1 (LASP-1) Inhibits Thyroid Cancer Cell Proliferation and Invasion.Oncol Res. 2017 Jul 5;25(6):879-886. doi: 10.3727/096504016X14785415155643. Epub 2016 Nov 17.
• [12] Functional analysis of a novel, thyroglobulin-embedded microRNA gene deregulated in papillary thyroid carcinoma.Sci Rep. 2017 Aug 30;7(1):9942. doi: 10.1038/s41598-017-10318-w.
• [13] MMP-11 promotes papillary thyroid cell proliferation and invasion via the NF-B pathway.J Cell Biochem. 2019 Feb;120(2):1860-1868. doi: 10.1002/jcb.27500. Epub 2018 Sep 1.
• [14] Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways.Oncogenesis. 2018 Nov 12;7(11):85. doi: 10.1038/s41389-018-0094-y.
• [15] NADPH oxidase NOX4 is a glycolytic regulator through mROS-HIF1 axis in thyroid carcinomas.Sci Rep. 2018 Oct 26;8(1):15897. doi: 10.1038/s41598-018-34154-8.
• [16] Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.Eur J Endocrinol. 2019 Apr 1;180(4):235-241. doi: 10.1530/EJE-18-0653.
• [17] Expression of the cAMP binding protein EPAC1 in thyroid tumors and growth regulation of thyroid cells and thyroid carcinoma cells by EPAC proteins.Horm Metab Res. 2015 Mar;47(3):200-8. doi: 10.1055/s-0034-1390484. Epub 2014 Nov 5.
• [18] Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2.PLoS One. 2018 May 7;13(5):e0196992. doi: 10.1371/journal.pone.0196992. eCollection 2018.
• [19] New Treatment of Medullary and Papillary Human Thyroid Cancer: Biological Effects of Hyaluronic Acid Hydrogel Loaded With Quercetin Alone or in Combination to an Inhibitor of Aurora Kinase.J Cell Physiol. 2016 Aug;231(8):1784-95. doi: 10.1002/jcp.25283. Epub 2016 Feb 2.
• [20] Cowden syndrome-associated germline succinate dehydrogenase complex subunit D (SDHD) variants cause PTEN-mediated down-regulation of autophagy in thyroid cancer cells.Hum Mol Genet. 2017 Apr 1;26(7):1365-1375. doi: 10.1093/hmg/ddx037.
• [21] Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother. 2013 Oct;67(8):723-30.
• [22] LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.Oncotarget. 2017 Apr 4;8(14):22954-22967. doi: 10.18632/oncotarget.14578.
• [23] SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway.Exp Ther Med. 2018 Jun;15(6):5007-5016. doi: 10.3892/etm.2018.6054. Epub 2018 Apr 12.
• [24] Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.APMIS. 2016 Apr;124(4):271-7. doi: 10.1111/apm.12505. Epub 2016 Jan 11.
• [25] Tiam1 promotes thyroid carcinoma metastasis by modulating EMT via Wnt/-catenin signaling.Exp Cell Res. 2018 Jan 15;362(2):532-540. doi: 10.1016/j.yexcr.2017.12.019. Epub 2017 Dec 22.
• [26] APRIL is overexpressed in cancer: link with tumor progression.BMC Cancer. 2009 Mar 16;9:83. doi: 10.1186/1471-2407-9-83.
• [27] Tumor Susceptibility Gene 101 Mediates Anoikis Resistance of Metastatic Thyroid Cancer Cells.Cancer Genomics Proteomics. 2018 Nov-Dec;15(6):473-483. doi: 10.21873/cgp.20106.
• [28] Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer.FEBS J. 2016 Jun;283(12):2326-39. doi: 10.1111/febs.13741. Epub 2016 May 12.
• [29] The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.J Endocrinol Invest. 2018 Nov;41(11):1275-1282. doi: 10.1007/s40618-018-0862-8. Epub 2018 Mar 15.
• [30] Alteration in the serum concentrations of FGF19, FGFR4 and Klotho in patients with thyroid cancer.Cytokine. 2018 May;105:32-36. doi: 10.1016/j.cyto.2018.02.013. Epub 2018 Feb 10.
• [31] Neurotrophin Receptors TrkA, p75(NTR), and Sortilin Are Increased and Targetable in Thyroid Cancer.Am J Pathol. 2018 Jan;188(1):229-241. doi: 10.1016/j.ajpath.2017.09.008. Epub 2017 Oct 14.
• [32] Long non-coding RNA TNRC6C-AS1 promotes methylation of STK4 to inhibit thyroid carcinoma cell apoptosis and autophagy via Hippo signalling pathway.J Cell Mol Med. 2020 Jan;24(1):304-316. doi: 10.1111/jcmm.14728. Epub 2019 Oct 27.
• [33] RAF-1 promotes survival of thyroid cancer cells harboring RET/PTC1 rearrangement independently of ERK activation.Mol Cell Endocrinol. 2015 Nov 5;415:64-75. doi: 10.1016/j.mce.2015.08.006. Epub 2015 Aug 8.
• [34] DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid cancer.Blood Cells Mol Dis. 2013 Mar;50(3):161-5. doi: 10.1016/j.bcmd.2012.10.009. Epub 2012 Nov 17.
• [35] Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2.Oncotarget. 2015 Oct 13;6(31):31780-91. doi: 10.18632/oncotarget.5566.
• [36] Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancer.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12473-81. eCollection 2015.
• [37] Erythropoietin in thyroid cancer.J Endocrinol Invest. 2006 Apr;29(4):320-9. doi: 10.1007/BF03344103.
• [38] Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma.BMC Cancer. 2013 Feb 15;13:79. doi: 10.1186/1471-2407-13-79.
• [39] A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer.Invest New Drugs. 2008 Apr;26(2):183-8. doi: 10.1007/s10637-007-9091-2. Epub 2007 Oct 2.
• [40] MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1.PLoS One. 2014 May 23;9(5):e96103. doi: 10.1371/journal.pone.0096103. eCollection 2014.
• [41] SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas.Surgery. 2014 Dec;156(6):1542-8; discussion 1548-9. doi: 10.1016/j.surg.2014.08.095. Epub 2014 Nov 11.
• [42] Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).Tumour Biol. 2014 Jul;35(7):6521-9. doi: 10.1007/s13277-014-1868-2. Epub 2014 Apr 1.
• [43] Plasmid-based Stat3-specific siRNA and GRIM-19 inhibit the growth of thyroid cancer cells in vitro and in vivo.Oncol Rep. 2014 Aug;32(2):573-80. doi: 10.3892/or.2014.3233. Epub 2014 Jun 5.
• [44] Pioglitazone Therapy of PAX8-PPAR Fusion Protein Thyroid Carcinoma.J Clin Endocrinol Metab. 2018 Apr 1;103(4):1277-1281. doi: 10.1210/jc.2017-02533.
• [45] Identification of thyroid carcinoma related genes with mRMR and shortest path approaches.PLoS One. 2014 Apr 9;9(4):e94022. doi: 10.1371/journal.pone.0094022. eCollection 2014.
• [46] Prostaglandin synthases influence thyroid follicular cell proliferation but not carcinogenesis in rats initiated with N-bis(2-hydroxypropyl)nitrosamine.Toxicol Sci. 2012 Jun;127(2):339-47. doi: 10.1093/toxsci/kfs097. Epub 2012 Mar 2.
• [47] RAIN Is a Novel Enhancer-Associated lncRNA That Controls RUNX2 Expression and Promotes Breast and Thyroid Cancer.Mol Cancer Res. 2020 Jan;18(1):140-152. doi: 10.1158/1541-7786.MCR-19-0564. Epub 2019 Oct 17.
• [48] Cancer-related genes transcriptionally induced by the fungicide penconazole.Toxicol In Vitro. 2014 Feb;28(1):125-30. doi: 10.1016/j.tiv.2013.06.006. Epub 2013 Jun 27.
• [49] Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers.Surgery. 2019 Jan;165(1):64-68. doi: 10.1016/j.surg.2018.05.077. Epub 2018 Nov 8.
• [50] Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.PLoS One. 2019 Feb 26;14(2):e0206309. doi: 10.1371/journal.pone.0206309. eCollection 2019.
• [51] Transient Receptor Potential Canonical 1 (TRPC1) Channels as Regulators of Sphingolipid and VEGF Receptor Expression: IMPLICATIONS FOR THYROID CANCER CELL MIGRATION AND PROLIFERATION.J Biol Chem. 2015 Jun 26;290(26):16116-31. doi: 10.1074/jbc.M115.643668. Epub 2015 May 13.
• [52] Expression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human carcinomas.PLoS One. 2014 Oct 15;9(10):e110094. doi: 10.1371/journal.pone.0110094. eCollection 2014.
• [53] AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.Cancers (Basel). 2019 Jun 7;11(6):785. doi: 10.3390/cancers11060785.
• [54] Ku80 gene knockdown by the CRISPR/Cas9 technique affects the biological functions of human thyroid carcinoma cells.Oncol Rep. 2019 Dec;42(6):2486-2498. doi: 10.3892/or.2019.7348. Epub 2019 Oct 1.
• [55] Activin A and activin receptors in thyroid cancer.Thyroid. 2001 Jan;11(1):3-14. doi: 10.1089/10507250150500603.
• [56] AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma.Cancer Med. 2016 Jul;5(7):1535-41. doi: 10.1002/cam4.698. Epub 2016 Mar 31.
• [57] miR-217 inhibits proliferation, migration, and invasion via targeting AKT3 in thyroid cancer.Biomed Pharmacother. 2017 Nov;95:1718-1724. doi: 10.1016/j.biopha.2017.09.074. Epub 2017 Oct 6.
• [58] Characterization of thyroid cancer driven by known and novel ALK fusions.Endocr Relat Cancer. 2019 Nov;26(11):803-814. doi: 10.1530/ERC-19-0325.
• [59] Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors.Free Radic Biol Med. 2010 Sep 15;49(6):997-1007. doi: 10.1016/j.freeradbiomed.2010.06.006. Epub 2010 Jun 11.
• [60] Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.J Exp Clin Cancer Res. 2016 Sep 6;35(1):135. doi: 10.1186/s13046-016-0410-3.
• [61] Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochem Biophys Res Commun. 2016 Jan 15;469(3):679-85. doi: 10.1016/j.bbrc.2015.12.008. Epub 2015 Dec 18.
• [62] Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.Anticancer Res. 2008 Jan-Feb;28(1A):139-44.
• [63] Classification of Benign and Malignant Thyroid Nodules Using a Combined Clinical Information and Gene Expression Signatures.PLoS One. 2016 Oct 24;11(10):e0164570. doi: 10.1371/journal.pone.0164570. eCollection 2016.
• [64] miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.BMC Cancer. 2017 Mar 4;17(1):170. doi: 10.1186/s12885-017-3158-z.
• [65] Characterization of a novel five-transmembrane domain cholecystokinin-2 receptor splice variant identified in human tumors.Mol Cell Endocrinol. 2012 Feb 26;349(2):170-9. doi: 10.1016/j.mce.2011.10.010. Epub 2011 Oct 25.
• [66] The multifaceted anti-cancer effects of BRAF-inhibitors.Oncotarget. 2019 Nov 12;10(61):6623-6640. doi: 10.18632/oncotarget.27304. eCollection 2019 Nov 12.
• [67] Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis.J Cell Mol Med. 2019 Sep;23(9):5907-5919. doi: 10.1111/jcmm.14386. Epub 2019 Jul 14.
• [68] Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis.J Endocrinol Invest. 2016 Nov;39(11):1285-1293. doi: 10.1007/s40618-016-0491-z. Epub 2016 Jun 1.
• [69] Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma.Cancer Res. 1998 May 15;58(10):2063-6.
• [70] Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy.Oncogene. 2017 Feb 2;36(5):667-677. doi: 10.1038/onc.2016.237. Epub 2016 Jul 4.
• [71] CCNG2 suppressor biological effects on thyroid cancer cell through promotion of CDK2 degradation.Asian Pac J Cancer Prev. 2013;14(10):6165-71. doi: 10.7314/apjcp.2013.14.10.6165.
• [72] Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser on STAT3 in prostate cancer cells.Am J Physiol Endocrinol Metab. 2013 Oct 15;305(8):E975-86. doi: 10.1152/ajpendo.00615.2012. Epub 2013 Aug 13.
• [73] Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels.Endocr Relat Cancer. 2010 Jun 1;17(2):317-28. doi: 10.1677/ERC-09-0016. Print 2010 Jun.
• [74] Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.Endocrine. 2019 Jan;63(1):94-100. doi: 10.1007/s12020-018-1762-6. Epub 2018 Sep 29.
• [75] Identification of Key Genes in Thyroid Cancer Microenvironment.Med Sci Monit. 2019 Dec 16;25:9602-9608. doi: 10.12659/MSM.918519.
• [76] Multiple anti-tumor effects of Reparixin on thyroid cancer.Oncotarget. 2017 May 30;8(22):35946-35961. doi: 10.18632/oncotarget.16412.
• [77] RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737. Epub 2011 Feb 16.
• [78] The expression and role of serum response factor in papillary carcinoma of the thyroid.Int J Oncol. 2009 Jul;35(1):49-55.
• [79] CYP24A1 depletion facilitates the antitumor effect of vitamin D3 on thyroid cancer cells.Exp Ther Med. 2018 Oct;16(4):2821-2830. doi: 10.3892/etm.2018.6536. Epub 2018 Jul 27.
• [80] Earlier Phases of Bone Scintigraphy Can Better Delineate the Extent of Soft Tissue Involvement of Bone Metastasis.Clin Nucl Med. 2018 Nov;43(11):854-856. doi: 10.1097/RLU.0000000000002260.
• [81] nc886, a non-coding RNA and suppressor of PKR, exerts an oncogenic function in thyroid cancer.Oncotarget. 2016 Nov 15;7(46):75000-75012. doi: 10.18632/oncotarget.11852.
• [82] ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population.Eur J Endocrinol. 2018 Jan;178(1):83-91. doi: 10.1530/EJE-17-0499. Epub 2017 Oct 18.
• [83] GPER1 in the thyroid: A systematic review.Life Sci. 2020 Jan 15;241:117112. doi: 10.1016/j.lfs.2019.117112. Epub 2019 Nov 29.
• [84] Development of Inflammatory Immune Response-Related Drugs Based on G Protein-Coupled Receptor Kinase 2.Cell Physiol Biochem. 2018;51(2):729-745. doi: 10.1159/000495329. Epub 2018 Nov 21.
• [85] Mitochondrial metabolism is inhibited by the HIF1-MYC-PGC-1 axis in BRAF V600E thyroid cancer.FEBS J. 2019 Apr;286(7):1420-1436. doi: 10.1111/febs.14786. Epub 2019 Mar 5.
• [86] The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.PLoS One. 2011;6(6):e20665. doi: 10.1371/journal.pone.0020665. Epub 2011 Jun 17.
• [87] HLA-G 3' untranslated region polymorphic sites associated with increased HLA-G production are more frequent in patients exhibiting differentiated thyroid tumours.Clin Endocrinol (Oxf). 2017 Apr;86(4):597-605. doi: 10.1111/cen.13289. Epub 2017 Jan 10.
• [88] TGF-1 induces HMGA1 expression: The role of HMGA1 in thyroid cancer proliferation and invasion.Int J Oncol. 2017 May;50(5):1567-1578. doi: 10.3892/ijo.2017.3958. Epub 2017 Apr 7.
• [89] HMGA2 Gene Expression in Fine-needle Aspiration Samples of Thyroid Nodules as a Marker for Preoperative Diagnosis of Thyroid Cancer.Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):471-476. doi: 10.1097/PAI.0000000000000637.
• [90] Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.Cancer Res. 2018 Aug 15;78(16):4642-4657. doi: 10.1158/0008-5472.CAN-17-1925. Epub 2018 May 14.
• [91] Mps1 is associated with the BRAF(V600E) mutation but does not rely on the classic RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma.Oncol Lett. 2018 Jun;15(6):9978-9986. doi: 10.3892/ol.2018.8561. Epub 2018 Apr 24.
• [92] Genetic polymorphisms in IL1R1 and IL1R2 are associated with susceptibility to thyroid cancer in the Chinese Han population.J Gene Med. 2019 Jun;21(6):e3093. doi: 10.1002/jgm.3093. Epub 2019 May 27.
• [93] Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression.Mod Pathol. 2010 Sep;23(9):1269-78. doi: 10.1038/modpathol.2010.117. Epub 2010 Jun 18.
• [94] ITCH is a putative target for a novel 20q11.22 amplification detected in anaplastic thyroid carcinoma cells by array-based comparative genomic hybridization.Cancer Sci. 2008 Oct;99(10):1940-9. doi: 10.1111/j.1349-7006.2008.00900.x.
• [95] Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer.Front Endocrinol (Lausanne). 2019 Aug 2;10:510. doi: 10.3389/fendo.2019.00510. eCollection 2019.
• [96] Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer.Cancers (Basel). 2019 Aug 12;11(8):1154. doi: 10.3390/cancers11081154.
• [97] Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11.
• [98] BRAF(V600E)-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT.Oncol Lett. 2019 Jul;18(1):927-935. doi: 10.3892/ol.2019.10360. Epub 2019 May 14.
• [99] Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression.Oncotarget. 2017 Nov 25;8(70):114980-114994. doi: 10.18632/oncotarget.22692. eCollection 2017 Dec 29.
• [100] Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.Cancers (Basel). 2019 Sep 17;11(9):1382. doi: 10.3390/cancers11091382.
• [101] A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.Clin Cancer Res. 2019 Sep 15;25(18):5475-5484. doi: 10.1158/1078-0432.CCR-18-1881. Epub 2019 Jun 11.
• [102] Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.World J Surg. 2006 May;30(5):767-74. doi: 10.1007/s00268-005-0308-2.
• [103] GPCR-mediated PI3K pathway mutations in pediatric and adult thyroid cancer.Oncotarget. 2019 Jun 25;10(41):4107-4124. doi: 10.18632/oncotarget.26993. eCollection 2019 Jun 25.
• [104] mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression.Int J Mol Sci. 2018 May 13;19(5):1448. doi: 10.3390/ijms19051448.
• [105] Thyroid cancer susceptibility and THRA1 and BAT-40 repeats polymorphisms.Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):638-42. doi: 10.1158/1055-9965.EPI-04-0424.
• [106] TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.J Clin Endocrinol Metab. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785.
• [107] NRG1 regulates redox homeostasis via NRF2 in papillary thyroid cancer.Int J Oncol. 2018 Aug;53(2):685-693. doi: 10.3892/ijo.2018.4426. Epub 2018 May 31.
• [108] Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.BMC Cancer. 2009 Oct 18;9:369. doi: 10.1186/1471-2407-9-369.
• [109] Human peptidylglycine alpha-amidating monooxygenase: cDNA, cloning and functional expression of a truncated form in COS cells.Biochem Biophys Res Commun. 1990 Jun 15;169(2):551-8. doi: 10.1016/0006-291x(90)90366-u.
• [110] Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance.Oncol Lett. 2019 Sep;18(3):2819-2824. doi: 10.3892/ol.2019.10639. Epub 2019 Jul 18.
• [111] E2F, HSF2, and miR-26 in thyroid carcinoma: bioinformatic analysis of RNA-sequencing data.Genet Mol Res. 2016 Mar 11;15(1):15017576. doi: 10.4238/gmr.15017576.
• [112] Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism.J Exp Clin Cancer Res. 2019 May 21;38(1):208. doi: 10.1186/s13046-019-1198-8.
• [113] The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis.Oncogene. 2004 Nov 4;23(52):8432-8. doi: 10.1038/sj.onc.1207766.
• [114] Family of microRNA-146 Regulates RAR in Papillary Thyroid Carcinoma.PLoS One. 2016 Mar 24;11(3):e0151968. doi: 10.1371/journal.pone.0151968. eCollection 2016.
• [115] Genome-wide gene expression profiles of thyroid carcinoma: Identification of molecular targets for treatment of thyroid carcinoma.Oncol Rep. 2008 Jul;20(1):105-21.
• [116] Tc-99m HYNIC-TOC scintigraphy in dedifferentiated thyroid cancer.BMJ Case Rep. 2019 Apr 1;12(4):e227910. doi: 10.1136/bcr-2018-227910.
• [117] Relaxin enhances the oncogenic potential of human thyroid carcinoma cells.Am J Pathol. 2006 Aug;169(2):617-32. doi: 10.2353/ajpath.2006.050876.
• [118] Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid.Virchows Arch. 2013 Jun;462(6):619-32. doi: 10.1007/s00428-013-1419-z. Epub 2013 May 4.
• [119] Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers.Oncogene. 2004 Feb 5;23(5):1117-24. doi: 10.1038/sj.onc.1207211.
• [120] CD133 promotes the self-renewal capacity of thyroid cancer stem cells through activation of glutamate aspartate transporter SLC1A3 expression.Biochem Biophys Res Commun. 2019 Mar 26;511(1):87-91. doi: 10.1016/j.bbrc.2019.02.023. Epub 2019 Feb 13.
• [121] Expression of OATP family members in hormone-related cancers: potential markers of progression.PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.
• [122] The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma.Genet Med. 2018 Sep;20(9):927-935. doi: 10.1038/gim.2017.224. Epub 2018 Jan 4.
• [123] Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet. 2012 Jan 15;21(2):300-10. doi: 10.1093/hmg/ddr459. Epub 2011 Oct 6.
• [124] Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62. doi: 10.1210/jcem.82.6.4013.
• [125] Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1.Oncol Rep. 2016 Jan;35(1):552-8. doi: 10.3892/or.2015.4358. Epub 2015 Oct 29.
• [126] Evaluation of Diagnostic Utility of Immunohistochemistry Markers of TROP-2 and HBME-1 in the Diagnosis of Thyroid Carcinoma.Eur Thyroid J. 2019 Jan;8(1):1-6. doi: 10.1159/000494430. Epub 2018 Nov 22.
• [127] Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death.Hum Mol Genet. 2001 Feb 1;10(3):251-8. doi: 10.1093/hmg/10.3.251.
• [128] Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.Endocrine. 2020 Jan;67(1):44-57. doi: 10.1007/s12020-019-02117-2. Epub 2019 Oct 26.
• [129] Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGF1 Axis.Clin Cancer Res. 2018 Dec 1;24(23):6078-6097. doi: 10.1158/1078-0432.CCR-18-0693. Epub 2018 Aug 3.
• [130] Thyroid Hormone Receptor- (TR) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.Endocrinology. 2016 Aug;157(8):3278-92. doi: 10.1210/en.2015-2046. Epub 2016 Jun 2.
• [131] Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.Invest New Drugs. 2009 Aug;27(4):297-303. doi: 10.1007/s10637-008-9174-8. Epub 2008 Sep 20.
• [132] Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny.Endocr Relat Cancer. 2019 Aug;26(8):713-725. doi: 10.1530/ERC-19-0176.
• [133] TXNIP overexpression suppresses proliferation and induces apoptosis in SMMC7221 cells through ROS generation and MAPK pathway activation.Oncol Rep. 2017 Jun;37(6):3369-3376. doi: 10.3892/or.2017.5577. Epub 2017 Apr 18.
• [134] Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake.Cancer Res. 2020 Jan 1;80(1):102-115. doi: 10.1158/0008-5472.CAN-19-1957. Epub 2019 Oct 31.
• [135] Excess of rare cancers in Werner syndrome (adult progeria).Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):239-46.
• [136] Role of chemokine receptors in thyroid cancer and immunotherapy.Endocr Relat Cancer. 2019 Aug;26(8):R465-R478. doi: 10.1530/ERC-19-0163.
• [137] The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells.Sci Rep. 2019 May 14;9(1):7374. doi: 10.1038/s41598-019-43894-0.
• [138] Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.Oncotarget. 2018 Jan 4;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 9.
• [139] Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.J Cell Mol Med. 2019 Dec;23(12):7974-7984. doi: 10.1111/jcmm.14460. Epub 2019 Sep 30.
• [140] IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5573-5584. doi: 10.1210/jc.2019-00040.
• [141] MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.Endocr Relat Cancer. 2019 Aug;26(8):699-712. doi: 10.1530/ERC-19-0188.
• [142] Activation of AMPK promotes thyroid cancer cell migration through its interaction with PKM2 and -catenin.Life Sci. 2019 Dec 15;239:116877. doi: 10.1016/j.lfs.2019.116877. Epub 2019 Oct 25.
• [143] The role of Slit2 as a tumor suppressor in thyroid cancer.Mol Cell Endocrinol. 2019 Mar 1;483:87-96. doi: 10.1016/j.mce.2019.01.010. Epub 2019 Jan 12.
• [144] Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism.Eur J Endocrinol. 2017 Sep;177(3):243-250. doi: 10.1530/EJE-17-0279. Epub 2017 Jun 2.
• [145] RAGE Mediates the Pro-Migratory Response of Extracellular S100A4 in Human Thyroid Cancer Cells.Thyroid. 2015 May;25(5):514-27. doi: 10.1089/thy.2014.0257. Epub 2015 Apr 3.
• [146] Effect of perioperative treatment with a hypoxia-inducible factor-1-alpha inhibitor in an orthotopic surgical mouse model of thyroid cancer.Anticancer Res. 2015 Apr;35(4):2049-54.
• [147] Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.Eur J Cancer. 2018 Nov;103:165-175. doi: 10.1016/j.ejca.2018.08.013. Epub 2018 Sep 22.
• [148] Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse.Int J Cancer. 2004 Jul 20;110(6):914-20. doi: 10.1002/ijc.20182.
• [149] Indomethacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation.Prostaglandins Other Lipid Mediat. 2001 May;65(1):11-20. doi: 10.1016/s0090-6980(01)00116-2.
• [150] Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines.J Cell Mol Med. 2019 Nov;23(11):7438-7448. doi: 10.1111/jcmm.14612. Epub 2019 Sep 9.
• [151] Gene Expression of CYP1A1 and its Possible Clinical Application in Thyroid Cancer Cases.Asian Pac J Cancer Prev. 2016;17(7):3477-82.
• [152] Haplotype analysis of XRCC1 gene polymorphisms and the risk of thyroid carcinoma.J BUON. 2018 Jan-Feb;23(1):234-243.
• [153] Glutathione S-transferase M1, T1, and P1 polymorphisms and thyroid cancer risk: a meta-analysis.Cancer Epidemiol. 2012 Dec;36(6):e333-40. doi: 10.1016/j.canep.2012.06.002. Epub 2012 Jul 4.
• [154] Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.Mol Endocrinol. 2005 Feb;19(2):527-39. doi: 10.1210/me.2004-0215. Epub 2004 Oct 14.
• [155] Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma.J Cancer. 2019 Jun 9;10(15):3543-3552. doi: 10.7150/jca.28364. eCollection 2019.
• [156] Afamin promotes glucose metabolism in papillary thyroid carcinoma.Mol Cell Endocrinol. 2016 Oct 15;434:108-15. doi: 10.1016/j.mce.2016.06.013. Epub 2016 Jun 18.
• [157] Effect of alkylglycerone phosphate synthase on the expression profile of circRNAs in the human thyroid cancer cell line FRO.Oncol Lett. 2018 May;15(5):7889-7899. doi: 10.3892/ol.2018.8356. Epub 2018 Mar 26.
• [158] Silencing of A-Kinase Anchor Protein 4 (AKAP4) Inhibits Proliferation and Progression of Thyroid Cancer.Oncol Res. 2017 Jul 5;25(6):873-878. doi: 10.3727/096504016X14783701102564. Epub 2016 Nov 8.
• [159] Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.Oncotarget. 2017 Apr 11;8(15):24457-24468. doi: 10.18632/oncotarget.14904.
• [160] Anoctamin5 regulates cell migration and invasion in thyroid cancer.Int J Oncol. 2017 Oct;51(4):1311-1319. doi: 10.3892/ijo.2017.4113. Epub 2017 Sep 1.
• [161] Comprehensive analysis of the clinical significance and prospective molecular mechanisms of differentially expressed autophagy-related genes in thyroid cancer.Int J Oncol. 2018 Aug;53(2):603-619. doi: 10.3892/ijo.2018.4404. Epub 2018 May 11.
• [162] The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.Oncotarget. 2017 Jun 30;8(46):80393-80404. doi: 10.18632/oncotarget.18902. eCollection 2017 Oct 6.
• [163] Restoration of Brain Acid Soluble Protein 1 Inhibits Proliferation and Migration of Thyroid Cancer Cells.Chin Med J (Engl). 2016 Jun 20;129(12):1439-46. doi: 10.4103/0366-6999.183434.
• [164] The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1.Cell Death Dis. 2018 Aug 29;9(9):871. doi: 10.1038/s41419-018-0933-y.
• [165] Identification of Novel Oncogenic Mutations inThyroid Cancer.J Am Coll Surg. 2016 Jun;222(6):1036-1043.e2. doi: 10.1016/j.jamcollsurg.2015.12.047. Epub 2016 Jan 14.
• [166] Iodine-131 treatment of thyroid cancer cells leads to suppression of cell proliferation followed by induction of cell apoptosis and cell cycle arrest by regulation of B-cell translocation gene 2-mediated JNK/NF-B pathways.Braz J Med Biol Res. 2017 Jan 16;50(1):e5933. doi: 10.1590/1414-431X20165933.
• [167] C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.Biochem Biophys Res Commun. 2017 Jan 22;482(4):590-596. doi: 10.1016/j.bbrc.2016.11.078. Epub 2016 Nov 15.
• [168] Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?.Front Endocrinol (Lausanne). 2018 Jun 21;9:314. doi: 10.3389/fendo.2018.00314. eCollection 2018.
• [169] CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer.Oncol Lett. 2018 Jul;16(1):105-112. doi: 10.3892/ol.2018.8653. Epub 2018 May 7.
• [170] Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.Cancer Lett. 2017 Dec 1;410:201-211. doi: 10.1016/j.canlet.2017.09.024. Epub 2017 Sep 23.
• [171] Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3.Oncotarget. 2016 Sep 6;7(36):57978-57990. doi: 10.18632/oncotarget.11154.
• [172] Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer.Medicine (Baltimore). 2016 Jan;95(4):e2592. doi: 10.1097/MD.0000000000002592.
• [173] A genome-wide association study yields five novel thyroid cancer risk loci.Nat Commun. 2017 Feb 14;8:14517. doi: 10.1038/ncomms14517.
• [174] An integrated analysis of cancer genes in thyroid cancer.Oncol Rep. 2016 Feb;35(2):962-70. doi: 10.3892/or.2015.4466. Epub 2015 Dec 1.
• [175] Emerging roles of circRNA_NEK6 targeting miR-370-3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway.Cancer Biol Ther. 2018;19(12):1139-1152. doi: 10.1080/15384047.2018.1480888. Epub 2018 Sep 12.
• [176] Knockdown of GATAD2A suppresses cell proliferation in thyroid cancer invitro.Oncol Rep. 2017 Apr;37(4):2147-2152. doi: 10.3892/or.2017.5436. Epub 2017 Feb 10.
• [177] Elevated HMGN4 expression potentiates thyroid tumorigenesis.Carcinogenesis. 2017 Apr 1;38(4):391-401. doi: 10.1093/carcin/bgx015.
• [178] HORMAD2 methylation-mediated epigenetic regulation of gene expression in thyroid cancer.J Cell Mol Med. 2018 Oct;22(10):4640-4652. doi: 10.1111/jcmm.13680. Epub 2018 Jul 24.
• [179] Tumour suppressive function of HUWE1 in thyroid cancer.J Biosci. 2016 Sep;41(3):395-405. doi: 10.1007/s12038-016-9623-z.
• [180] Loss-of-function of IFT88 determines metabolic phenotypes in thyroid cancer.Oncogene. 2018 Aug;37(32):4455-4474. doi: 10.1038/s41388-018-0211-6. Epub 2018 May 10.
• [181] THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2307-2312. doi: 10.1073/pnas.1614265114. Epub 2017 Feb 13.
• [182] IL-17RB enhances thyroid cancer cell invasion and metastasis via ERK1/2 pathway-mediated MMP-9 expression.Mol Immunol. 2017 Oct;90:126-135. doi: 10.1016/j.molimm.2017.06.034. Epub 2017 Jul 15.
• [183] Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met/PI3K/Akt signaling pathway.Biomed Pharmacother. 2018 Feb;98:265-270. doi: 10.1016/j.biopha.2017.12.045. Epub 2017 Dec 27.
• [184] Activating KIR2DS5 receptor is a risk for thyroid cancer.Hum Immunol. 2012 Oct;73(10):1017-22. doi: 10.1016/j.humimm.2012.07.325. Epub 2012 Jul 23.
• [185] Coupling of LETM1 up-regulation with oxidative phosphorylation and platelet-derived growth factor receptor signaling via YAP1 transactivation.Oncotarget. 2016 Oct 11;7(41):66728-66739. doi: 10.18632/oncotarget.11456.
• [186] LRP4 promotes proliferation, migration, and invasion in papillary thyroid cancer.Biochem Biophys Res Commun. 2018 Sep 3;503(1):257-263. doi: 10.1016/j.bbrc.2018.06.012. Epub 2018 Jun 11.
• [187] MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling.Biochem Biophys Res Commun. 2017 Sep 9;491(1):72-78. doi: 10.1016/j.bbrc.2017.07.044. Epub 2017 Jul 8.
• [188] A novel tumor suppressor gene NCOA5 is correlated with progression in papillary thyroid carcinoma.Onco Targets Ther. 2018 Jan 11;11:307-311. doi: 10.2147/OTT.S154158. eCollection 2018.
• [189] E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin.Cell Death Dis. 2018 Sep 24;9(10):987. doi: 10.1038/s41419-018-1001-3.
• [190] Positive Feedback Loops Between NrCAM and Major Signaling Pathways Contribute to Thyroid Tumorigenesis.J Clin Endocrinol Metab. 2017 Feb 1;102(2):613-624. doi: 10.1210/jc.2016-1677.
• [191] Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation.Cell Commun Signal. 2019 Feb 13;17(1):12. doi: 10.1186/s12964-019-0322-x.
• [192] Poly r(C) binding protein (PCBP) 1 expression is regulated at the post-translation level in thyroid carcinoma.Am J Transl Res. 2017 Feb 15;9(2):708-714. eCollection 2017.
• [193] Therapeutic effects of adenovirus-mediated CD and NIS expression combined with Na(131)I/5-FC on human thyroid cancer.Oncol Lett. 2017 Dec;14(6):7431-7436. doi: 10.3892/ol.2017.7175. Epub 2017 Oct 12.
• [194] Differential expression of PIWIL2 in papillary thyroid cancers.Gene. 2018 Apr 5;649:8-13. doi: 10.1016/j.gene.2018.01.066. Epub 2018 Jan 31.
• [195] A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers.Fam Cancer. 2017 Oct;16(4):561-566. doi: 10.1007/s10689-017-9984-y.
• [196] The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population.Thyroid. 2015 Mar;25(3):333-40. doi: 10.1089/thy.2014.0431. Epub 2015 Feb 5.
• [197] MiR-150 Inhibits Cell Growth In Vitro and In Vivo by Restraining the RAB11A/WNT/-Catenin Pathway in Thyroid Cancer.Med Sci Monit. 2017 Oct 12;23:4885-4894. doi: 10.12659/msm.906997.
• [198] Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E).Oncotarget. 2017 Sep 24;8(49):84743-84760. doi: 10.18632/oncotarget.21262. eCollection 2017 Oct 17.
• [199] Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma.Rom J Morphol Embryol. 2013;54(3):499-503.
• [200] A somatic mutation of RasGRP3 decreases Na(+)/I(-) symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway.Am J Cancer Res. 2018 Sep 1;8(9):1847-1855. eCollection 2018.
• [201] Analysis of ribonuclease activity in sub-nanoliter droplets by label-free fluorescence measurements.Analyst. 2017 Jul 10;142(14):2610-2616. doi: 10.1039/c6an02724e.
• [202] Solute carrier family 35 member F2 is indispensable for papillary thyroid carcinoma progression through activation of transforming growth factor- type I receptor/apoptosis signal-regulating kinase 1/mitogen-activated protein kinase signaling axis.Cancer Sci. 2018 Mar;109(3):642-655. doi: 10.1111/cas.13478. Epub 2018 Feb 1.
• [203] LncRNA SPRY4-IT was concerned with the poor prognosis and contributed to the progression of thyroid cancer.Cancer Gene Ther. 2018 Feb;25(1-2):39-46. doi: 10.1038/s41417-017-0003-0. Epub 2017 Dec 12.
• [204] HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.BMC Med Genet. 2016 Aug 17;17(1):60. doi: 10.1186/s12881-016-0323-1.
• [205] An epistatic interaction between the PAX8 and STK17B genes in papillary thyroid cancer susceptibility.PLoS One. 2013 Sep 23;8(9):e74765. doi: 10.1371/journal.pone.0074765. eCollection 2013.
• [206] Effect of Interferon- on the Basal and the TNF-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation.Mediators Inflamm. 2016;2016:8512417. doi: 10.1155/2016/8512417. Epub 2016 Jul 31.
• [207] Silencing of TCTN1 inhibits proliferation, induces cell cycle arrest and apoptosis in human thyroid cancer.Exp Ther Med. 2017 Oct;14(4):3720-3726. doi: 10.3892/etm.2017.4940. Epub 2017 Aug 16.
• [208] Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulating miRNA-214.Int J Oncol. 2017 Feb;50(2):708-716. doi: 10.3892/ijo.2016.3803. Epub 2016 Dec 14.
• [209] TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.Oncol Rep. 2017 Mar;37(3):1555-1564. doi: 10.3892/or.2017.5364. Epub 2017 Jan 13.
• [210] Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/-catenin signaling pathway.Biomed Pharmacother. 2017 Dec;96:98-103. doi: 10.1016/j.biopha.2017.09.132. Epub 2017 Sep 29.
• [211] CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.Oncogene. 2013 May 30;32(22):2726-38. doi: 10.1038/onc.2012.301. Epub 2012 Jul 16.
• [212] Rewiring of the apoptotic TGF--SMAD/NFB pathway through an oncogenic function of p27 in human papillary thyroid cancer.Oncogene. 2017 Feb 2;36(5):652-666. doi: 10.1038/onc.2016.233. Epub 2016 Jul 25.
• [213] A nested case-control study of polychlorinated biphenyls, organochlorine pesticides, and thyroid cancer in the Janus Serum Bank cohort.Environ Res. 2018 Aug;165:125-132. doi: 10.1016/j.envres.2018.04.012. Epub 2018 Apr 23.
• [214] FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1.Endocr Relat Cancer. 2020 Mar;27(3):137-151. doi: 10.1530/ERC-19-0156.
• [215] Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo.Clin Cancer Res. 2018 Aug 15;24(16):4030-4043. doi: 10.1158/1078-0432.CCR-17-3167. Epub 2018 Apr 24.
• [216] Knockdown of IQGAP1 inhibits proliferation and epithelial-mesenchymal transition by Wnt/-catenin pathway in thyroid cancer.Onco Targets Ther. 2017 Mar 13;10:1549-1559. doi: 10.2147/OTT.S128564. eCollection 2017.
• [217] Mutant MYO1F alters the mitochondrial network and induces tumor proliferation in thyroid cancer.Int J Cancer. 2018 Oct 1;143(7):1706-1719. doi: 10.1002/ijc.31548. Epub 2018 May 7.
• [218] Steroid receptor coactivator-1 interacts with NF-B to increase VEGFC levels in human thyroid cancer.Biosci Rep. 2018 Jun 12;38(3):BSR20180394. doi: 10.1042/BSR20180394. Print 2018 Jun 29.
• [219] Gene master regulators of papillary and anaplastic thyroid cancers.Oncotarget. 2017 Dec 19;9(2):2410-2424. doi: 10.18632/oncotarget.23417. eCollection 2018 Jan 5.
• [220] Pictorial Representation of Illness and Self Measure-Revised 2 (PRISM-R2): an effective tool to assess perceived burden of thyroid cancer in mainland China.Support Care Cancer. 2018 Sep;26(9):3267-3275. doi: 10.1007/s00520-018-4172-7. Epub 2018 Apr 11.
• [221] PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.J Biomed Nanotechnol. 2014 Jul;10(7):1249-58. doi: 10.1166/jbn.2014.1862.
• [222] EBP1 suppresses growth, migration, and invasion of thyroid cancer cells through upregulating RASAL expression.Tumour Biol. 2015 Nov;36(11):8325-31. doi: 10.1007/s13277-015-3523-y. Epub 2015 May 26.
• [223] Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer.Endocr Relat Cancer. 2015 Apr;22(2):121-30. doi: 10.1530/ERC-14-0537.
• [224] The high expression of TC1 (C8orf4) was correlated with the expression of -catenin and cyclin D1 and the progression of squamous cell carcinomas of the tongue.Tumour Biol. 2015 Sep;36(9):7061-7. doi: 10.1007/s13277-015-3423-1. Epub 2015 Apr 14.
• [225] Vitamin D receptor expression is linked to potential markers of human thyroid papillary carcinoma.J Steroid Biochem Mol Biol. 2016 May;159:26-30. doi: 10.1016/j.jsbmb.2016.02.016. Epub 2016 Feb 22.
• [226] Effect of ABCE1-silencing gene, transfected by electrotransfer, on the proliferation, invasion, and migration of human thyroid carcinoma SW579 cells.Genet Mol Res. 2015 Nov 23;14(4):14680-9. doi: 10.4238/2015.November.18.32.
• [227] Transcriptional regulation of the potential tumor suppressor ABI3 gene in thyroid carcinomas: interplay between methylation and NKX2-1 availability.Oncotarget. 2016 May 3;7(18):25960-70. doi: 10.18632/oncotarget.8416.
• [228] The levels of NF-B p50 and NF-B p65 play a role in thyroid carcinoma malignancy in vivo.J Int Med Res. 2018 Oct;46(10):4092-4099. doi: 10.1177/0300060518785846. Epub 2018 Jul 17.
• [229] Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker?.Med Sci Monit. 2015 Jun 16;21:1745-51. doi: 10.12659/MSM.893597.
• [230] MiR-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1.Biochem Biophys Res Commun. 2015 Sep 4;464(4):1128-1133. doi: 10.1016/j.bbrc.2015.07.090. Epub 2015 Jul 20.
• [231] CDH16/Ksp-cadherin is expressed in the developing thyroid gland and is strongly down-regulated in thyroid carcinomas.Endocrinology. 2012 Jan;153(1):522-34. doi: 10.1210/en.2011-1572. Epub 2011 Oct 25.
• [232] Loss of CPSF2 expression is associated with increased thyroid cancer cellular invasion and cancer stem cell population, and more aggressive disease.J Clin Endocrinol Metab. 2014 Jul;99(7):E1173-82. doi: 10.1210/jc.2013-4140. Epub 2014 Mar 21.
• [233] X-ray repair cross-complementing group 1(XRCC1) genetic polymorphisms and thyroid carcinoma risk: a meta-analysis.Asian Pac J Cancer Prev. 2012;13(12):6385-90. doi: 10.7314/apjcp.2012.13.12.6385.
• [234] Expression of miR-100 and RBSP3 in FTC-133 cells after exposure to 131I.Nucl Med Commun. 2014 Sep;35(9):932-8. doi: 10.1097/MNM.0000000000000142.
• [235] DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.Anticancer Res. 2013 Nov;33(11):4833-9.
• [236] Quantitative assessment of the association between GNB3 C825T polymorphism and cancer risk.J BUON. 2014 Oct-Dec;19(4):1092-5.
• [237] The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression.Oncogene. 2012 Sep 6;31(36):4012-21. doi: 10.1038/onc.2011.569. Epub 2011 Dec 12.
• [238] Helicase-like transcription factor: a new marker of well-differentiated thyroid cancers.BMC Cancer. 2014 Jul 8;14:492. doi: 10.1186/1471-2407-14-492.
• [239] HOXC10 up-regulation contributes to human thyroid cancer and indicates poor survival outcome.Mol Biosyst. 2015 Nov;11(11):2946-54. doi: 10.1039/c5mb00253b.
• [240] Mismatch repair single nucleotide polymorphisms and thyroid cancer susceptibility.Oncol Lett. 2018 May;15(5):6715-6726. doi: 10.3892/ol.2018.8103. Epub 2018 Feb 21.
• [241] Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.BMC Cancer. 2013 Oct 8;13:462. doi: 10.1186/1471-2407-13-462.
• [242] FAM129A regulates autophagy in thyroid carcinomas in an oncogene-dependent manner.Endocr Relat Cancer. 2019 Jan 1;26(1):227-238. doi: 10.1530/ERC-17-0530.
• [243] Identification of targets of Twist1 transcription factor in thyroid cancer cells.J Clin Endocrinol Metab. 2014 Sep;99(9):E1617-26. doi: 10.1210/jc.2013-3799. Epub 2014 May 21.
• [244] Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.Mol Cancer. 2013 Oct 20;12(1):124. doi: 10.1186/1476-4598-12-124.
• [245] REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.Oncotarget. 2015 Nov 17;6(36):39211-24. doi: 10.18632/oncotarget.5391.
• [246] RTN4IP1 is down-regulated in thyroid cancer and has tumor-suppressive function.J Clin Endocrinol Metab. 2013 Mar;98(3):E446-54. doi: 10.1210/jc.2012-3180. Epub 2013 Feb 7.
• [247] SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.Int J Clin Exp Pathol. 2015 Oct 1;8(10):12276-83. eCollection 2015.
• [248] Down-regulation of miR-218-2 and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer.J Clin Endocrinol Metab. 2013 Aug;98(8):E1334-44. doi: 10.1210/jc.2013-1053. Epub 2013 May 29.
• [249] Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.Chin Med J (Engl). 2012 Oct;125(19):3526-31.
• [250] SPC24 is critical for anaplastic thyroid cancer progression.Oncotarget. 2017 Mar 28;8(13):21884-21891. doi: 10.18632/oncotarget.15670.
• [251] Novel antiapoptotic effect of TBX15: overexpression of TBX15 reduces apoptosis in cancer cells.Apoptosis. 2015 Oct;20(10):1338-46. doi: 10.1007/s10495-015-1155-8.
• [252] Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion.Endocr Relat Cancer. 2008 Sep;15(3):787-99. doi: 10.1677/ERC-08-0079. Epub 2008 Jun 17.
• [253] Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas.Br J Cancer. 2003 Apr 22;88(8):1223-8. doi: 10.1038/sj.bjc.6600876.
• [254] XB130, a novel adaptor protein, promotes thyroid tumor growth.Am J Pathol. 2011 Jan;178(1):391-401. doi: 10.1016/j.ajpath.2010.11.024. Epub 2010 Dec 23.
• [255] Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.J Clin Invest. 2005 Jan;115(1):94-101. doi: 10.1172/JCI23237.
• [256] The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer.Clin Cancer Res. 2007 Aug 15;13(16):4713-20. doi: 10.1158/1078-0432.CCR-07-0618.
• [257] Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.J Biol Chem. 2007 May 25;282(21):15490-7. doi: 10.1074/jbc.M610586200. Epub 2007 Apr 4.
• [258] Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin in FTC-133 cells.Biochim Biophys Acta. 2011 May;1813(5):695-703. doi: 10.1016/j.bbamcr.2011.02.004. Epub 2011 Feb 17.
• [259] Identification of LRP-1 as an endocytosis and recycling receptor for 1-integrin in thyroid cancer cells.Oncotarget. 2017 Aug 10;8(45):78614-78632. doi: 10.18632/oncotarget.20201. eCollection 2017 Oct 3.
• [260] Heterochromatin protein 1 expression is reduced in human thyroid malignancy.Lab Invest. 2014 Jul;94(7):788-95. doi: 10.1038/labinvest.2014.68. Epub 2014 May 19.
• [261] The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.Cancer Lett. 2015 Feb 28;357(2):535-41. doi: 10.1016/j.canlet.2014.12.010. Epub 2014 Dec 9.
• [262] CD82, and CD63 in thyroid cancer.Int J Mol Med. 2004 Oct;14(4):517-27.
• [263] CDC23 regulates cancer cell phenotype and is overexpressed in papillary thyroid cancer.Endocr Relat Cancer. 2011 Nov 28;18(6):731-42. doi: 10.1530/ERC-11-0181. Print 2011.
• [264] An essential role for Pax8 in the transcriptional regulation of cadherin-16 in thyroid cells.Mol Endocrinol. 2012 Jan;26(1):67-78. doi: 10.1210/me.2011-1090. Epub 2011 Dec 1.
• [265] Activating mutations of the TSH receptor in differentiated thyroid carcinomas.Oncogene. 1995 Nov 2;11(9):1907-11.
• [266] Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues.Int J Cancer. 2006 Jul 15;119(2):275-82. doi: 10.1002/ijc.21842.
• [267] GINS2 promotes cell proliferation and inhibits cell apoptosis in thyroid cancer by regulating CITED2 and LOXL2.Cancer Gene Ther. 2019 Mar;26(3-4):103-113. doi: 10.1038/s41417-018-0045-y. Epub 2018 Sep 4.
• [268] Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues.Int J Mol Med. 2002 Apr;9(4):373-6.
• [269] CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis.Cancer Res. 2008 Sep 1;68(17):7156-64. doi: 10.1158/0008-5472.CAN-08-1085.
• [270] Anchored multiplex PCR for targeted next-generation sequencing.Nat Med. 2014 Dec;20(12):1479-84. doi: 10.1038/nm.3729. Epub 2014 Nov 10.
• [271] The Impact of Cysteine-Rich Intestinal Protein 1 (CRIP1) on Thyroid Carcinoma.Cell Physiol Biochem. 2017;43(5):2037-2046. doi: 10.1159/000484184. Epub 2017 Oct 23.
• [272] Methylation of DACT2 accelerates esophageal cancer development by activating Wnt signaling.Oncotarget. 2016 Apr 5;7(14):17957-69. doi: 10.18632/oncotarget.7647.
• [273] Strong association between an HLA-DR antigen and thyroid carcinoma.Tissue Antigens. 1982 Aug;20(2):155-8. doi: 10.1111/j.1399-0039.1982.tb00340.x.
• [274] Genetic Variants Implicate Dual Oxidase-2 in Familial and Sporadic Nonmedullary Thyroid Cancer.Cancer Res. 2019 Nov 1;79(21):5490-5499. doi: 10.1158/0008-5472.CAN-19-0721. Epub 2019 Sep 9.
• [275] Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.Surgery. 2005 Dec;138(6):1102-9; discussion 1109-10. doi: 10.1016/j.surg.2005.05.025.
• [276] Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway.Mol Biol Rep. 2019 Jun;46(3):2665-2678. doi: 10.1007/s11033-019-04698-7. Epub 2019 Apr 26.
• [277] Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer.J Clin Endocrinol Metab. 2011 Mar;96(3):E554-65. doi: 10.1210/jc.2010-1800. Epub 2010 Dec 29.
• [278] Loss of HITS (FAM107B) expression in cancers of multiple organs: tissue microarray analysis.Int J Oncol. 2012 Oct;41(4):1347-57. doi: 10.3892/ijo.2012.1550. Epub 2012 Jul 10.
• [279] Differential expression of IgG Fc binding protein (FcgammaBP) in human normal thyroid tissue, thyroid adenomas and thyroid carcinomas.J Endocrinol. 2002 Sep;174(3):517-24. doi: 10.1677/joe.0.1740517.
• [280] Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.Am J Pathol. 2005 Jul;167(1):223-31. doi: 10.1016/s0002-9440(10)62967-7.
• [281] INT-2 gene amplification in differentiated human thyroid cancer.Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4. doi: 10.1055/s-0029-1211713.
• [282] Case Report of Birt-Hogg-Dub Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.Medicine (Baltimore). 2016 May;95(22):e3695. doi: 10.1097/MD.0000000000003695.
• [283] Oleanolic acid inhibits cell proliferation migration and invasion and induces SW579 thyroid cancer cell line apoptosis by targeting forkhead transcription factor A.Anticancer Drugs. 2019 Sep;30(8):812-820. doi: 10.1097/CAD.0000000000000777.
• [284] The long non-coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the miR-1-CCND2 axis.Am J Cancer Res. 2017 Jun 1;7(6):1298-1309. eCollection 2017.
• [285] The Effect of Hexavalent Chromium on the Incidence and Mortality of Human Cancers: A Meta-Analysis Based on Published Epidemiological Cohort Studies.Front Oncol. 2019 Feb 4;9:24. doi: 10.3389/fonc.2019.00024. eCollection 2019.
• [286] Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5.Cancer Res. 1998 Jan 15;58(2):198-203.
• [287] Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.J Surg Oncol. 2012 Mar 15;105(4):357-64. doi: 10.1002/jso.22113. Epub 2011 Oct 17.
• [288] Phospholipase D inhibitors reduce human prostate cancer cell proliferation and colony formation.Br J Cancer. 2018 Jan;118(2):189-199. doi: 10.1038/bjc.2017.391. Epub 2017 Nov 14.
• [289] Comprehensive Assessment of GPR68 Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody.Int J Mol Sci. 2019 Oct 23;20(21):5261. doi: 10.3390/ijms20215261.
• [290] Improved determination of variant erythrocytes at the glycophorin A (GPA) locus and variant frequency in patients treated with radioiodine for thyroid cancer.Int J Radiat Biol. 1996 Aug;70(2):131-43. doi: 10.1080/095530096145120.
• [291] Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review.Clin Endocrinol (Oxf). 2017 Jun;86(6):837-844. doi: 10.1111/cen.13316. Epub 2017 Mar 23.
• [292] Embryonic develop-associated gene 1 is overexpressed and acts as a tumor promoter in thyroid carcinoma.Biomed Pharmacother. 2016 Jul;81:86-92. doi: 10.1016/j.biopha.2016.03.052. Epub 2016 Apr 9.
• [293] Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53.Int J Cancer. 1998 Jan 30;75(3):391-5. doi: 10.1002/(sici)1097-0215(19980130)75:3<391::aid-ijc11>3.0.co;2-c.
• [294] Induction of epithelial-mesenchymal transition (EMT) by Beclin 1 knockdown via posttranscriptional upregulation of ZEB1 in thyroid cancer cells.Oncotarget. 2016 Oct 25;7(43):70364-70377. doi: 10.18632/oncotarget.12217.
• [295] Hsa-miR-139-5p is a prognostic thyroid cancer marker involved in HNRNPF-mediated alternative splicing.Int J Cancer. 2020 Jan 15;146(2):521-530. doi: 10.1002/ijc.32622. Epub 2019 Aug 28.
• [296] Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma.Hum Pathol. 2018 Nov;81:105-112. doi: 10.1016/j.humpath.2018.06.016. Epub 2018 Jun 25.
• [297] A novel homeobox gene overexpressed in thyroid carcinoma.Thyroid. 2004 Jul;14(7):500-5. doi: 10.1089/1050725041517020.
• [298] Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.J Clin Endocrinol Metab. 2006 Mar;91(3):1119-28. doi: 10.1210/jc.2005-1826. Epub 2006 Jan 4.
• [299] Expression of insulin-like growth factor I (IGF-I) gene and of genes for IGF-binding proteins 1, 2, 3, 4 (IGFBP-1-IGFBP-4) in non-neoplastic human thyroid cells and in certain human thyroid cancers. Effect of exogenous IGF-I on this expression.Endocr Res. 2004 Feb;30(1):47-59. doi: 10.1081/erc-120028484.
• [300] Suppression of Tafazzin promotes thyroid cancer apoptosis via activating the JNK signaling pathway and enhancing INF2-mediated mitochondrial fission.J Cell Physiol. 2019 Sep;234(9):16238-16251. doi: 10.1002/jcp.28287. Epub 2019 Feb 11.
• [301] INSL-3 is expressed in human hyperplastic and neoplastic thyrocytes.Int J Oncol. 2003 May;22(5):993-1001.
• [302] MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways.J Cell Physiol. 2019 Aug;234(10):18382-18391. doi: 10.1002/jcp.28472. Epub 2019 Apr 2.
• [303] Characterisation of DEHAL1 expression in thyroid pathologies.Eur J Endocrinol. 2007 Mar;156(3):295-301. doi: 10.1530/EJE-06-0596.
• [304] RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas.Mol Cell Biol. 1996 Oct;16(10):5335-45. doi: 10.1128/MCB.16.10.5335.
• [305] KLLN epigenotype-phenotype associations in Cowden syndrome.Eur J Hum Genet. 2015 Nov;23(11):1538-43. doi: 10.1038/ejhg.2015.8. Epub 2015 Feb 11.
• [306] LRG? enhances the migration of thyroid carcinoma cells through promotion of the epithelialmesenchymal transition by activating MAPK/p38 signaling.Oncol Rep. 2019 Jun;41(6):3270-3280. doi: 10.3892/or.2019.7123. Epub 2019 Apr 17.
• [307] Knockdown of Latent Transforming Growth Factor- (TGF-)-Binding Protein 2 (LTBP2) Inhibits Invasion and Tumorigenesis in Thyroid Carcinoma Cells.Oncol Res. 2017 Apr 14;25(4):503-510. doi: 10.3727/096504016X14755368915591. Epub 2016 Oct 5.
• [308] Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.J Clin Endocrinol Metab. 2009 Apr;94(4):1467-71. doi: 10.1210/jc.2008-2378. Epub 2009 Feb 3.
• [309] MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling.J Clin Invest. 2019 Mar 1;129(3):1015-1029. doi: 10.1172/JCI97712. Epub 2019 Jan 28.
• [310] Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells.Cancer Lett. 2019 Feb 1;442:362-372. doi: 10.1016/j.canlet.2018.11.010. Epub 2018 Nov 14.
• [311] Identification of novel diagnostic biomarkers for thyroid carcinoma.Oncotarget. 2017 Dec 4;8(67):111551-111566. doi: 10.18632/oncotarget.22873. eCollection 2017 Dec 19.
• [312] Survey of dentin sialophosphoprotein and its cognate matrix metalloproteinase-20 in human cancers.Cancer Med. 2019 May;8(5):2167-2178. doi: 10.1002/cam4.2117. Epub 2019 Apr 1.
• [313] Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.J Clin Endocrinol Metab. 2006 Jul;91(7):2704-12. doi: 10.1210/jc.2006-0492. Epub 2006 Apr 18.
• [314] HLA-DR alpha gene regulation in immortalized human thyroid cancer cells.Clin Immunol Immunopathol. 1993 May;67(2):151-6. doi: 10.1006/clin.1993.1058.
• [315] Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression.Am J Transl Res. 2019 Mar 15;11(3):1760-1770. eCollection 2019.
• [316] Napsin A Expression in Subtypes of Thyroid Tumors: Comparison with Lung Adenocarcinomas.Endocr Pathol. 2020 Mar;31(1):39-45. doi: 10.1007/s12022-019-09600-6.
• [317] The antioxidant function of Bcl-2 preserves cytoskeletal stability of cells with defective respiratory complex I.Cell Mol Life Sci. 2008 Sep;65(18):2943-51. doi: 10.1007/s00018-008-8300-2.
• [318] Overexpression of NDRG2 Increases Iodine Uptake and Inhibits Thyroid Carcinoma Cell Growth In Situ and In Vivo.Oncol Res. 2016 Jan 21;23(1-2):43-51. doi: 10.3727/096504015X14452563486093.
• [319] Human herpes simplex viruses in benign and malignant thyroid tumours.J Pathol. 2010 Jun;221(2):193-200. doi: 10.1002/path.2701.
• [320] Two-dimensional complementary deoxyribonucleic acid electrophoresis revealing up-regulated human epididymal protein-1 and down-regulated CL-100 in thyroid papillary carcinoma.Endocrinology. 2002 Nov;143(11):4422-8. doi: 10.1210/en.2002-220550.
• [321] NR2F1-AS1 regulated miR-423-5p/SOX12 to promote proliferation and invasion of papillary thyroid carcinoma.J Cell Biochem. 2020 Feb;121(2):2009-2018. doi: 10.1002/jcb.29435. Epub 2019 Nov 6.
• [322] Overexpression of NOTCH-regulated Ankyrin Repeat Protein is associated with papillary thyroid carcinoma progression.PLoS One. 2017 Feb 16;12(2):e0167782. doi: 10.1371/journal.pone.0167782. eCollection 2017.
• [323] Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth.Endocr J. 1999 Apr;46(2):243-52. doi: 10.1507/endocrj.46.243.
• [324] Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer.Mutat Res. 2019 Nov;816-818:111672. doi: 10.1016/j.mrfmmm.2019.111672. Epub 2019 Jun 1.
• [325] Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.Cancer Res. 2006 Feb 1;66(3):1491-9. doi: 10.1158/0008-5472.CAN-05-2514.
• [326] Expression of the ring ligase PRAJA2 in thyroid cancer.J Clin Endocrinol Metab. 2012 Nov;97(11):4253-9. doi: 10.1210/jc.2012-2360. Epub 2012 Sep 4.
• [327] Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34.Nutr Cancer. 2010;62(1):66-73. doi: 10.1080/01635580903191569.
• [328] RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma. Cancer. 2006 Dec 15;107(12):2752-9. doi: 10.1002/cncr.22325.
• [329] Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.Thyroid. 2011 Apr;21(4):391-9. doi: 10.1089/thy.2010.0168.
• [330] The role of prospero homeobox 1 (PROX1) expression in follicular thyroid carcinoma cells.Oncotarget. 2017 Dec 12;8(69):114136-114155. doi: 10.18632/oncotarget.23167. eCollection 2017 Dec 26.
• [331] REG potentiates TGF-/Smad signal dependent epithelial-mesenchymal transition in thyroid cancer cells.Cell Signal. 2019 Dec;64:109412. doi: 10.1016/j.cellsig.2019.109412. Epub 2019 Sep 3.
• [332] RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism.Cell Signal. 2006 Dec;18(12):2272-82. doi: 10.1016/j.cellsig.2006.05.016. Epub 2006 May 24.
• [333] Fine-needle aspiration biopsy-RT-PCR expression analysis of prothymosin alpha and parathymosin in thyroid: novel proliferation markers?.Neoplasma. 2007;54(1):57-62.
• [334] Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.Oncogene. 2017 Sep 14;36(37):5296-5308. doi: 10.1038/onc.2017.154. Epub 2017 May 15.
• [335] Screening of specific changes in mRNAs in thyroid tumors by sequence specific differential display: decreased expression of c-fos mRNA in papillary carcinoma.Endocr J. 1999 Jun;46(3):459-66. doi: 10.1507/endocrj.46.459.
• [336] RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.J Endocrinol Invest. 2008 Oct;31(10):893-9. doi: 10.1007/BF03346438.
• [337] Role of receptor activity modifying protein 1 in function of the calcium sensing receptor in the human TT thyroid carcinoma cell line.PLoS One. 2014 Jan 13;9(1):e85237. doi: 10.1371/journal.pone.0085237. eCollection 2014.
• [338] RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.Onco Targets Ther. 2017 Jan 9;10:247-257. doi: 10.2147/OTT.S124417. eCollection 2017.
• [339] Frequent epigenetic inactivation of RASSF10 in thyroid cancer.Epigenetics. 2009 Nov 16;4(8):571-6. doi: 10.4161/epi.4.8.10056. Epub 2009 Nov 14.
• [340] Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.Mol Cancer. 2010 Sep 29;9:264. doi: 10.1186/1476-4598-9-264.
• [341] RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer.J Clin Endocrinol Metab. 2007 Apr;92(4):1458-66. doi: 10.1210/jc.2006-2199. Epub 2007 Jan 23.
• [342] RCAN1-4 is a thyroid cancer growth and metastasis suppressor.JCI Insight. 2017 Mar 9;2(5):e90651. doi: 10.1172/jci.insight.90651.
• [343] Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomas.PLoS One. 2010 Sep 22;5(9):e12701. doi: 10.1371/journal.pone.0012701.
• [344] Relaxin enhances the collagenolytic activity and in vitro invasiveness by upregulating matrix metalloproteinases in human thyroid carcinoma cells.Mol Cancer Res. 2011 Jun;9(6):673-87. doi: 10.1158/1541-7786.MCR-10-0411. Epub 2011 Apr 14.
• [345] The tumor suppressor gene TRC8/RNF139 is disrupted by a constitutional balanced translocation t(8;22)(q24.13;q11.21) in a young girl with dysgerminoma.Mol Cancer. 2009 Jul 30;8:52. doi: 10.1186/1476-4598-8-52.
• [346] Overexpression of the HIP gene coding for a heparin/heparan sulfate-binding protein in human thyroid carcinomas.Cancer Res. 1998 Oct 15;58(20):4745-51.
• [347] Low expression of ryanodine receptor 2 is associated with poor prognosis in thyroid carcinoma.Oncol Lett. 2019 Oct;18(4):3605-3612. doi: 10.3892/ol.2019.10732. Epub 2019 Aug 7.
• [348] Modern approaches to age-old questions about thyroid tumors.Thyroid. 2005 Jun;15(6):575-82. doi: 10.1089/thy.2005.15.575.
• [349] Germline Heterozygous Variants in SEC23B Are Associated with Cowden Syndrome and Enriched in Apparently Sporadic Thyroid Cancer. Am J Hum Genet. 2015 Nov 5;97(5):661-76. doi: 10.1016/j.ajhg.2015.10.001. Epub 2015 Oct 29.
• [350] Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells.BMC Cancer. 2013 Dec 5;13:574. doi: 10.1186/1471-2407-13-574.
• [351] SIRT4 inhibits the proliferation, migration, and invasion abilities of thyroid cancer cells by inhibiting glutamine metabolism.Onco Targets Ther. 2019 Mar 28;12:2397-2408. doi: 10.2147/OTT.S189536. eCollection 2019.
• [352] SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.Oncogene. 2019 Jan;38(3):345-359. doi: 10.1038/s41388-018-0434-6. Epub 2018 Aug 9.
• [353] Thyroid tumorigenesis and molecular markers in thyroid cancer.Curr Opin Oncol. 2010 Jan;22(1):23-9. doi: 10.1097/CCO.0b013e328333846f.
• [354] The cellular localization of autotaxin impacts on its biological functions in human thyroid carcinoma cells.Oncol Rep. 2008 Jun;19(6):1485-91.
• [355] miR-4319 inhibited the development of thyroid cancer by modulating FUS-stabilized SMURF1.J Cell Biochem. 2020 Jan;121(1):174-182. doi: 10.1002/jcb.29026. Epub 2019 May 30.
• [356] Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers.Clin Cancer Res. 2016 Sep 1;22(17):4491-504. doi: 10.1158/1078-0432.CCR-15-2461. Epub 2016 Mar 30.
• [357] Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression.J Pathol. 2017 Nov;243(3):342-353. doi: 10.1002/path.4951.
• [358] Ras oncogene-mediated progressive silencing of extracellular superoxide dismutase in tumorigenesis.Biomed Res Int. 2015;2015:780409. doi: 10.1155/2015/780409. Epub 2015 Oct 15.
• [359] Downregulation of microR-147b represses the proliferation and invasion of thyroid carcinoma cells by inhibiting Wnt/-catenin signaling via targeting SOX15.Mol Cell Endocrinol. 2020 Feb 5;501:110662. doi: 10.1016/j.mce.2019.110662. Epub 2019 Nov 21.
• [360] Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer.J Clin Endocrinol Metab. 2009 Nov;94(11):4613-8. doi: 10.1210/jc.2009-0703. Epub 2009 Oct 9.
• [361] Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dub tumour suppressor gene (FLCN).Oncogene. 2014 Feb 20;33(8):956-65. doi: 10.1038/onc.2013.27. Epub 2013 Feb 18.
• [362] Expression of SSX genes in human tumors.Int J Cancer. 1998 Jul 3;77(1):19-23. doi: 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2.
• [363] Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.Am J Pathol. 2018 Nov;188(11):2653-2661. doi: 10.1016/j.ajpath.2018.07.012. Epub 2018 Aug 18.
• [364] Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.BMC Cancer. 2006 Nov 1;6:260. doi: 10.1186/1471-2407-6-260.
• [365] Genetic markers to discriminate benign and malignant thyroid nodules with undetermined cytology in an area of borderline iodine deficiency.J Endocrinol Invest. 2012 Sep;35(8):754-9. doi: 10.3275/8012. Epub 2011 Oct 4.
• [366] Characterization and chromosomal mapping of the human TFG gene involved in thyroid carcinoma.Genomics. 1997 May 1;41(3):327-31. doi: 10.1006/geno.1997.4625.
• [367] Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas.Br J Cancer. 2006 Dec 4;95(11):1529-36. doi: 10.1038/sj.bjc.6603455. Epub 2006 Oct 31.
• [368] Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.J Cancer Res Clin Oncol. 2007 Apr;133(4):213-8. doi: 10.1007/s00432-006-0159-8. Epub 2006 Oct 28.
• [369] Thymosin beta-10 gene expression as a possible tool in diagnosis of thyroid neoplasias.Oncol Rep. 2004 Aug;12(2):239-43.
• [370] Oncometabolites as biomarkers in thyroid cancer: a systematic review.Cancer Manag Res. 2019 Feb 25;11:1829-1841. doi: 10.2147/CMAR.S188661. eCollection 2019.
• [371] TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells.Endocr Relat Cancer. 2016 Sep;23(9):699-709. doi: 10.1530/ERC-16-0063. Epub 2016 Jul 15.
• [372] Papillary thyroid carcinoma in a boy with familial tuberous sclerosis complex attributable to a TSC2 deletion-a case report.Curr Oncol. 2017 Oct;24(5):e423-e428. doi: 10.3747/co.24.3555. Epub 2017 Oct 25.
• [373] Downregulation of TSPAN13 by miR-369-3p inhibits cell proliferation in papillary thyroid cancer (PTC).Bosn J Basic Med Sci. 2019 May 20;19(2):146-154. doi: 10.17305/bjbms.2018.2865.
• [374] Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells.Cancer Res. 2001 May 1;61(9):3640-6.
• [375] Downregulated long noncoding RNA LINC00313 inhibits the epithelial-mesenchymal transition, invasion, and migration of thyroid cancer cells through inhibiting the methylation of ALX4.J Cell Physiol. 2019 Nov;234(11):20992-21004. doi: 10.1002/jcp.28703. Epub 2019 May 15.
• [376] Expression of serum AMPD1 in thyroid carcinoma and its clinical significance.Exp Ther Med. 2018 Apr;15(4):3357-3361. doi: 10.3892/etm.2018.5859. Epub 2018 Feb 12.
• [377] Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.Endocr Pathol. 2019 Dec;30(4):262-269. doi: 10.1007/s12022-019-09589-y.
• [378] Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression.Endocr Metab Immune Disord Drug Targets. 2020;20(4):591-598. doi: 10.2174/1871530319666191018170022.
• [379] Serum deprivation response functions as a tumor suppressor gene in papillary thyroid cancer.Clin Genet. 2019 Nov;96(5):418-428. doi: 10.1111/cge.13609. Epub 2019 Jul 31.
• [380] Generation and identification of a thyroid cancer cell line with stable expression of CCDC67 and luciferase reporter genes.Oncol Lett. 2019 Nov;18(5):4495-4502. doi: 10.3892/ol.2019.10839. Epub 2019 Sep 10.
• [381] The role of EIF1AX in thyroid cancer tumourigenesis and progression.J Endocrinol Invest. 2019 Mar;42(3):313-318. doi: 10.1007/s40618-018-0919-8. Epub 2018 Jul 2.
• [382] Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.Recent Pat Anticancer Drug Discov. 2019;14(3):226-241. doi: 10.2174/1574892814666190726143011.
• [383] Long non-coding RNA BANCR regulates cancer stem cell markers in papillary thyroid cancer via the RAF/MEK/ERK signaling pathway.Oncol Rep. 2018 Aug;40(2):859-866. doi: 10.3892/or.2018.6502. Epub 2018 Jun 18.
• [384] Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.Oncotarget. 2017 Apr 18;8(16):27075-27092. doi: 10.18632/oncotarget.15635.
• [385] Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.Biomed Pharmacother. 2019 Aug;116:108966. doi: 10.1016/j.biopha.2019.108966. Epub 2019 May 16.
• [386] IGSF1: A novel oncogene regulates the thyroid cancer progression.Cell Biochem Funct. 2019 Oct;37(7):516-524. doi: 10.1002/cbf.3426. Epub 2019 Jul 25.
• [387] In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.Cancer Discov. 2015 Jul;5(7):740-51. doi: 10.1158/2159-8290.CD-14-1347. Epub 2015 Apr 16.
• [388] Comprehensive Exploration to Identify Predictive DNA Markers of Np63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma.Ann Surg Oncol. 2019 Dec;26(13):4814-4825. doi: 10.1245/s10434-019-07795-w. Epub 2019 Sep 16.
• [389] A ceRNA Circuitry Involving the Long Noncoding RNA Klhl14-AS, Pax8, and Bcl2 Drives Thyroid Carcinogenesis.Cancer Res. 2019 Nov 15;79(22):5746-5757. doi: 10.1158/0008-5472.CAN-19-0039. Epub 2019 Sep 26.
• [390] LIMD2 targeted by miR?4a promotes the proliferation and invasion of nonsmall cell lung cancer cells.Mol Med Rep. 2018 Nov;18(5):4760-4766. doi: 10.3892/mmr.2018.9464. Epub 2018 Sep 6.
• [391] LRIG1 negatively regulates RET mutants and is downregulated in thyroid cancer.Int J Oncol. 2018 Apr;52(4):1189-1197. doi: 10.3892/ijo.2018.4273. Epub 2018 Feb 9.
• [392] Mst1 overexpression combined with Yap knockdown augments thyroid carcinoma apoptosis via promoting MIEF1-related mitochondrial fission and activating the JNK pathway.Cancer Cell Int. 2019 May 22;19:143. doi: 10.1186/s12935-019-0860-8. eCollection 2019.
• [393] Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy.J Photochem Photobiol B. 2019 Aug;197:111534. doi: 10.1016/j.jphotobiol.2019.111534. Epub 2019 Jun 15.
• [394] MicroRNA-592 suppresses the malignant phenotypes of thyroid cancer by regulating lncRNA NEAT1 and downregulating NOVA1.Int J Mol Med. 2019 Sep;44(3):1172-1182. doi: 10.3892/ijmm.2019.4278. Epub 2019 Jul 16.
• [395] Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.Cancers (Basel). 2018 Mar 27;10(4):92. doi: 10.3390/cancers10040092.
• [396] Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression.Oncol Lett. 2019 Sep;18(3):3227-3235. doi: 10.3892/ol.2019.10632. Epub 2019 Jul 18.
• [397] miR-206 inhibits thyroid cancer proliferation and invasion by targeting RAP1B.J Cell Biochem. 2019 Nov;120(11):18927-18936. doi: 10.1002/jcb.29213. Epub 2019 Jun 27.
• [398] RRS1 gene expression involved in the progression of papillary thyroid carcinoma.Cancer Cell Int. 2018 Feb 13;18:20. doi: 10.1186/s12935-018-0519-x. eCollection 2018.
• [399] MiR-299-3p functions as a tumor suppressor in thyroid cancer by regulating SHOC2.Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):232-240. doi: 10.26355/eurrev_201901_16769.
• [400] Iodine promotes thyroid cancer development via SPANXA1 through the PI3K/AKT signalling pathway.Oncol Lett. 2019 Jul;18(1):637-644. doi: 10.3892/ol.2019.10391. Epub 2019 May 21.
• [401] TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway.Cell Death Dis. 2019 May 21;10(6):397. doi: 10.1038/s41419-019-1600-7.
• [402] TFCP2/TFCP2L1/UBP1 transcription factors in cancer.Cancer Lett. 2018 Apr 28;420:72-79. doi: 10.1016/j.canlet.2018.01.078. Epub 2018 Feb 7.
• [403] TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.Biomed Pharmacother. 2019 Dec;120:109508. doi: 10.1016/j.biopha.2019.109508. Epub 2019 Oct 22.